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ABSTRACT 
Shiga toxin-producing Escherichia coli (STEC) strains are important food-borne 
pathogens that have been linked to human illness. In the United States, STEC O157:H7 
strains have been attributed to the majority of disease and outbreaks; however, the 
frequency of disease associated with STEC non-O157 strains have also increased and is 
often under recognized due to diagnostic limitations. In 2012, the Food Safety and 
Inspection Service (FSIS) implemented mandatory testing for non-O157 STEC serogroups 
O26, O45, O103, O111, O121, and O145. Single nucleotide polymorphisms (SNPs) have 
been identified in the O-antigen gene cluster for each of the non-O157 STEC serogroups 
that can differentiate between a STEC and non-STEC strain. In this study, the multiplex 
oligonucleotide ligation-PCR (MOL-PCR) detection platform was adapted for the 
detection and characterization of the above-described non-O157 STEC serogroups. The 
SNP-based MOL-PCR assay has demonstrated the ability to simultaneously detect the non-
O157 serogroups and characterize the strain based on the SNP discriminates identified for 
each serogroup. This work provides a potential diagnostic platform that can reduce 
diagnostic limitations for the detection of non-O157 serogroups. 
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Chapter 1: Introduction 
1.1 Shiga Toxin Family 
1.1.1 Structure of Shiga Toxins 
The Shiga toxin family is a group of bacterial protein toxins that are comprised of 
Shigella dysenteriae (S.dysenteriae) serotype 1 and Shiga toxins produced by Escherichia 
coli (E.coli), otherwise known as Shiga toxin-producing E.coli (STEC). 1-2 The structure 
of the Shiga toxin (stx) protein consists of an AB5 molecular configuration, with an A and 
B-subunit that are conserved across the Shiga toxin family.3-4 The A-subunit is a 32-kDa 
protein that contains two cysteine residues (Cys-242 and Cys-261) that are covalently 
linked through a disulfide bond.5-6 Through proteolytic cleavage by trypsin or furin, the A-
subunit is divided into two components, A1 (27.5 kDa) and A2 (4.5 kDa) fragments, with 
the fragments remaining attached via a disulfide bridge.3-8 The A1 fragment contains the N-
glycosidase catalytic site that is associated with inhibition of protein synthesis.7 The A2 
fragment includes the carboxyl-terminal tail that functions to bind the A-subunit to the B-
subunit, resulting in the formation of an α-helix that is enclosed by the B-subunit, as 
illustrated in Figure 1.1.5, 8The B-subunit is a pentameric protein that consists of five 
identical B-subunits (7.7-kDA) that are responsible for attaching to host cellular receptors 
(Figure 1.1).8-9 The stx B-subunits bind to the receptor glycosphingolipid 
globotriaosylceramide (Gb3) located on the cellular surface.9  
The molecular structure for each B-subunit is comprised of three Gb3 binding sites 
(carbohydrate binding sites), resulting in an stx B-subunit that can potentially bind to 15 
Gb3 binding sites.9 As a result, the potential stx B-subunit binding sites leads to high-
affinity binding, with an approximate binding affinity of 109 M-1 (103 M-1 per Gb3 binding 
2 
 
site).10 With the molecular configuration of the B-subunit, the conformation of the B-
subunit allows for high-affinity binding that can be related to increased cellular toxicity.   
 
Figure 1.1: A) Graphical representation of the Shiga toxin structure. The A-subunit is shown in red and 
represents the A1 and A2 fragments. The B-subunit consists of a 5-pentameric ring. B) The structure of stx 
represented in a ribbon diagram.8 Figure adapted from Johannes et al. 2010. Ribbon structure created in VMD 
[PDB 1DM0].8 
1.1.2 AB5 Toxin Structure for Stx1 and Stx2  
 Shiga toxins associated with E.coli contain a comparable A-B structure to that 
found in S. dysenteriae.1 Within STEC, the existence of two stx proteins have been 
identified, Shiga toxin 1 (stx1) and Shiga toxin 2 (stx2).11 Shiga toxins generated by S. 
dysenteriae and stx1 from E.coli have similar A-subunits and identical B-subunits.12-13 The 
A-subunit of stx1 varies by three nucleotides, leading to an alteration in the amino acid 
sequence at the catalytic site of the A-subunit.2, 12 Stx1 and stx2 contain a similar toxin 
structure and function; however, stx2 is comprised of only 56% of the same amino acid 
sequence as stx1.14 Specifically, the A-subunit and B-subunit of stx2 are comprised of 55% 
and 57% of the amino acid sequence found in stx1, respectively.14  
The molecular conformation for stx2 varies in both the A and B-subunit in 
comparison to the stx conformation.5 The catalytic active site for stx2 is positioned on a 
B. A. 
A-Subunit 
B-Subunit 
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portion of the B-pentamer that allows for accessibility to the A1 fragment.
5 The A2 fragment 
extends through the pore of the B-pentamer, allowing for the formation of an α-helix at the 
surface of cellular receptors (Figure 1.2).5 In contrast to the A-subunit of stx2, the 
accessibility of the A-subunit on stx and stx1 is blocked by the A2 fragment; therefore, 
hindering catalytic activity prior to proteolytic cleavage of the A-subunit into A1 and A2 
fragments.3-8 As for the B-subunit, variation in the Gb3 binding sites have been identified 
between stx and stx2.  
 
Figure 1. 2: A) Illustration of the structure of Shiga toxin 2 produced by E.coli. The A-subunit is represented 
in blue and shows the Al and A2 fragments, with the A2 fragment traversing the pore of the B-subunit. The 
B-subunit is comprised of a pentameric ring. B) A ribbon diagram of Stx2 with identical color scheme to 
graphical representation.5 Figure adapted from Johannes et al. 2010. Ribbon structure created in VMD [PDB 
1R4P]. 
 
Stx2 varies in conformation and amino acid sequence at the carbohydrate binding 
site 2, which may be attributed to variation in Gb3 binding affinities between stx1 and stx2.5 
The distinction in Gb3 binding affinity between stx1 and stx2 may be associated with the 
role of pathogenicity in human illness.  
A. B. 
A-Subunit 
B-Subunit 
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1.2 Role of Stx in Human Illness 
 The role of stx in human illness begins with binding of the B-pentamer to the 
trisaccharide region of Gb3 located on the plasma membrane of the cell.1 Expression of 
Gb3 is often observed in kidney epithelium and endothelium, microvascular endothelial 
cells located in intestinal lamina propria, and platelets.1 After the B-pentameric moiety 
binds to Gb3, Shiga toxins are endocytosed into the cell.1 A common method for the uptake 
of Shiga toxins is through clathrin-coated pits.1 Clathrin has been identified as a protein 
that allows for the formation of coated vesicles and contributes to the uptake of stx into the 
cell.1 The toxin is then transported through the trans-Golgi network, the Golgi apparatus, 
and the endoplasmic reticulum.1,3 The A-subunit is translocated into the cytoplasm, where 
the A1 subunit cleaves an adenine residue from 28S rRNA of the 60S ribosomal unit. 
1-7 As 
a result, protein synthesis is inhibited within the cell, leading to apoptosis.1,3 Therefore, stx 
contributes to the disruption of protein synthesis and leads to human illness that could be 
potentially life threatening.  
1.3 Human Illness Associated with STEC 
 Escherichia coli (E.coli) is a diverse bacterial species that is considered a part of 
the microbiota of the digestive tract of both humans and animals.11 E.coli strains can be 
classified as commensal or pathogenic bacteria that have been associated with 
gastrointestinal disease.3, 11 Pathogenic STEC strains have been linked to intestinal and 
extraintestinal disease, including hemorrhagic colitis (HC) and hemolytic-uremic 
syndrome (HUS).3 The gastrointestinal disease HC includes symptoms accompanied by 
abdominal pain and watery diarrhea that may progress to bloody diarrhea.3 Human STEC 
infections can progress to potentially life threatening HUS that is characterized by low 
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platelet count (thrombocytopenia), microangiopathic hemolytic anemia, and acute renal 
failure.3  
STEC infections account for 265,000 infections in the United States annually, with 
5 to 10 percent of infections developing into potentially life-threatening HUS.16 Pathogenic 
STEC strains that are often associated with human illness and outbreaks consist of E.coli 
O157:H7 and non-O157 E.coli strains.16 In the United States, E.coli O157:H7 strains 
contribute to 73,000 illnesses, while non-O157 strains contribute to 37,000 illnesses 
annually.16-17 STEC infections lead to considerable economic cost to society. In 2005, the 
cost of STEC infections was estimated to be 405 million dollars.18 The estimated cost of 
STEC infections was in relation to the cost of medical care, decrease in job productivity, 
and infections that lead to premature death.18 The CDC estimates that 85 percent of STEC 
infections occur as a result of food contamination.16 Significant cost of STEC infections 
have led to increased regulation in food processing and understanding the routes of 
transmission for STEC. 
1.4 Reservoirs and Routes of Transmission for STEC 
1.4.1 Potential Reservoirs for STEC 
The epidemiology for STEC infections in humans can be evaluated with the farm- 
to-fork model. Ruminants represent a group of mammals that are considered a natural 
reservoir for STEC.11 STEC is present in the gastrointestinal microbiota of healthy cattle 
and ruminants.19 Dairy and beef cattle are considered a principal reservoir for STEC and 
have been implicated as a source of transmission for food-borne illness.11 Major factors 
that contribute to prevalence of STEC in cattle include life stage of the cow and seasonality. 
Life stage is predictive of prevalence of STEC, with STEC often detected in calves and 
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heifers and decreasing in occurrence in adult cattle. 20 E.coli O157:H7 is often found in the 
excrement of cattle; specifically, weaned calves show higher prevalence (4.9 to 5.3%) of 
shedding in comparison to pre-weaned calves (1.5 to 2.9%).20 Seasonality is another factor 
that contributes to the transmission of STEC. The patterns of STEC outbreaks are often 
correlated with patterns of E.coli O157:H7 and non-O157 shedding in herds.21 In particular, 
excrement shedding of E.coli O157:H7 during the summer (12.9%) is higher than during 
winter months (0.3%).21 As for non-O157, prevalence of non-O157 in cattle excrement was 
found to be at 19.3%, which was considerably higher than O157:H7.21   
1.4.2 Routes of Transmission for STEC 
 The routes of transmission for STEC include infections associated with food-borne 
pathogens and exposure to the environment. Most often, STEC infections arise from food-
borne pathogens, such as undercooked beef products or unpasteurized milk.22 STEC 
infections have also been linked to unpasteurized apple juice, mayonnaise, and 
vegetables.22 Determination of transmission of STEC can be attributed to food preparation. 
It has been estimated that 34% of E.coli O157:H7 related illnesses can be prevented by 
proper hand-washing to avoid cross-contamination.23 In addition, water contamination 
with STEC is also a source of transmission, with potential water contamination arising 
from excrement that has been washed into the water supply, rivers, and dams.23 Other 
sources of STEC transmission include direct contact with farm animals and person-to-
person transmission.23  
1.5 Characterization of STEC Strains 
  STEC that has been implicated as a source for human illness can be characterized 
by the serogroup. Identification of STEC serogroups are categorized by the O (Ohne) 
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antigen11 The O-antigen is a component of the lipopolysaccharide (LPS) of Gram-negative 
E.coli.24 Located on the outermost portion of LPS, the O-antigen consists of a repeating 
oligosaccharide unit that contains one to eight glycosyl residues (Figure 1.3).25 The O-
antigen varies by sugar composition, sugar sequences, chemical linkages, and substitution 
of sugar residues.25 Structural variability within the O-antigen has led to identification of 
over 181 serogroups.24 The variability of genes that compose the O-antigen are highly 
specific and allow for proper identification of E.coli serogroups.26 
 Characterization of STEC strains can also be performed by serotype.11 The serotype 
is determined by the O-antigen and the H (Hauch) antigen.11 The H-antigen identifies the 
presence of flagellar proteins.11 Serotyping of STEC strains allows for the differentiation 
between STEC serotypes; including STEC O157:H7 and non-O157 STEC strains.11 The 
O-antigen gene cluster used to differentiate STEC serogroups can also differentiate 
between STEC and non-STEC strains.26 Specifically, single nucleotide polymorphisms 
(SNPs) have been identified within the O-antigen gene cluster for non-O157 E.coli 
serogroups O26, O45, O103, O111, O121,and O145.26  SNPs located within the O-antigen 
gene cluster have been utilized for identification of serogroups and pathotypes.26 SNP 
variation between serogroups have the ability to differentiate between STEC and non-
STEC strains, which is predictive of variation amongst O-antigen gene clustering.26 
Furthermore, SNPs identified within specific genes located in specific serogroups have 
been identified for characterization of non-O157 strains.26 Based on high specificity and 
selectivity for detecting the STEC allele in STEC strains, nucleic acid-based assays have 
been developed for the detection of STEC signatures. 
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Figure 1.3: Schematic for the basic structure of lipopolysaccharide (LPS) that is located on the outer 
membrane of gram negative E.coli. The O-antigen is labeled in blue and contains repeating oligosaccharide 
subunits that contribute to variability in sugar composition and the identification of over 181 serogroups.25 
The Core is divided into the inner and outer core that consist of hexose sugars (glucose, galactose, etc.) and 
3-deoxy-D-manno-octulosonic acid (Kdo), respectively.25 Lipid A is responsible for endotoxic activity and 
is composed of β-D-GlcN-(1-6)-α-D-GlcN disaccharide each containing phosphate groups( red circles).25 
Figure adapted from Erridge et al. 2002.  
1.6 Diagnostics for Detection of stx 
1.6.1 Tissue Cytotoxicity Assays for stx Detection 
Technologies for detection and characterization of STEC are important for both 
public notification of outbreaks and clinical management.27 Rapid and sensitive diagnostic 
methods for STEC are essential for timely mitigation and treatment. Current diagnostic 
methods are designed to detect the presence of stx in fecal samples and STEC isolates.27The 
detection of stx by tissue culture is considered the “gold standard.” 27 Specifically, tissue 
culture cytotoxicity assays that utilize African green monkey kidney cells or Vero cells 
have been employed, due to the high concentration of Gb3 and Gb4 receptors present 
within their plasma membranes.27 Vero cells are plated in a monolayer and subject to fecal 
culture filtrates.27 Strains of E.coli that contain stx  produce a cytopathogenic effect on the 
cultured Vero cells, otherwise known as Vero cytotoxin-producing E.coli (VTEC) .27  As 
a result, tissue culture with Vero cells is considered a highly sensitive diagnostic method 
for the detection of both stx1 and stx2 in fecal samples.27 Although considered the “gold 
O-Antigen Core Lipid A 
Outer  Inner 
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standard,” tissue culture cytotoxicity assays are not a rapid diagnostic method and require 
48 to 72 hours for results.27 In addition, tissue cytotoxicity assays are incapable of 
differentiating between different types of pathogens that produce Shiga toxins and do not 
have the ability to characterize the strain by serotype.  
1.6.2 Enzyme-linked Immunosorbent Assays (ELISA) for stx Detection  
Another method for STEC detection is the enzyme-linked immunosorbent assays 
(ELISA) that have the capability of detecting stx1 and stx2 in clinical and food samples.28 
ELISA utilizes enzyme-labelled antibodies for STEC detection by using polyclonal or 
monoclonal antibodies that are specific to O and H antigens.28 The type of ELISA often 
used for the detection of STEC is the sandwich ELISA.28 The polyclonal or monoclonal 
antibodies are capture ligands that bind to the antigen of specific toxins.28 The detection 
event for ELISA occurs when an stx detection antibody is added to the bound capture 
ligand, followed by incubation with an anti-immunoglobulin enzyme conjugate that 
signifies the presence of the antigen through color formation.28 ELISA is considered less 
sensitive than Vero cytotoxicity assays due to the inability for ELISA to detect stx at low 
concentrations in fecal extracts (<50 pg/mL).28 In comparison, ELISA has the capability to 
detect stx in fecal cultures where stx is present at higher concentrations (>100 pg/mL).28 
ELISA is considered both a rapid and sensitive detection system when evaluating fecal 
cultures, with results obtained within 1 day.28 
1.7 Molecular Diagnostics for Detection of stx genes 
Molecular diagnostics have been employed as a rapid and sensitive detection 
method for identifying pathogenic markers.29 Assay development utilizing genomic 
markers to identify STEC genomic signatures, provides both a rapid and highly sensitive 
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detection system.29 Identification of nucleotide sequences for stx1 and stx2 genes have 
allowed for the design of oligonucleotide primers for amplification of stx genes through 
polymerase chain reaction (PCR).28 Nucleic acid-based assays can be classified into two 
types of amplification; target amplification or signal amplification.29 Target amplification 
techniques that are often associated with STEC detection are multiplex PCR and multiplex 
real-time PCR (RT-PCR). STEC detection methods for signal amplification include 
Multiplex ligase-dependent probe amplification (MLPA) and Multiplex oligonucleotide 
ligation-PCR (MOL-PCR). 29 
1.7.1 Multiplex PCR for Detection of stx genes 
Multiplex PCR for the detection of stx1 and stx2 genes in STEC isolates and fecal 
samples is the most common target amplification technique. The identification of 
nucleotide sequences for stx1 and stx2 have allowed for the design of synthetic 
oligonucleotide primers for target amplification through Multiplex-PCR.30 Multiplex-PCR 
allows for simultaneous detection of STEC genomic markers (stx1, stx2, eae, etc.) and 
characterization of STEC in a single tube reaction.29-30 In the presence of a specific target, 
oligonucleotide sequences can amplify specific DNA sequences generating amplified 
copies of the target of interest.31 Amplified products are often detected through end point 
detection by gel or capillary electrophoresis.29 
The addition of multiple primer pairs for the detection of a specific genomic marker 
presents multiple disadvantages. With the presence of multiple oligonucleotide primers, 
primer sequences in multiplex may vary in GC content leading to variation in time of 
denaturation and reduction in amplification efficiency.31 Differences in length of PCR 
primer and GC content lead to variation in melting temperature (Tm); therefore, designing 
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PCR primers with similar Tm is vital for successful amplification of PCR product.31 In 
addition, designing multiple oligonucleotide primers requires careful selection of primer 
sequences to prevent primer dimer formation, due to portions of the primer sequence that 
are complementary to other primers.31 As a result, the potential disadvantages for PCR 
primer design for multiplex-PCR contributes to a decreased level of multiplexing.31  
Another disadvantage for multiplex-PCR is the analysis of multiplex PCR products. 
End point detection of PCR products is a cumbersome technique that is not considered a 
high throughput technique.29 Gel electrophoresis separates PCR products based on the size 
of the DNA fragment.31 Designing primers with similar amplicon size presents a challenge 
when differentiating between PCR products through gel electrophoresis.31 To increase 
reliability of multiplex-PCR,  multiplex-PCR is often coupled with nucleic acid 
microarrays and real-time PCR for the detection of amplified PCR products.31  
1.7.2 Multiplex Real Time-PCR for Detection stx genes 
Multiplex RT-PCR is a technology that allows for the detection and quantification 
of genomic signatures.29 Real-time PCR assays utilize TaqMan or molecular beacon probes 
that are comprised of synthetic oligonucleotide sequences that are conjugated to a 
fluorophore (5’) and a quencher (3’).33 The quencher functions to quench the fluorescent 
emission of the fluorophore prior to modification of the oligonucleotide probe, while the 
fluorophore serves as the reporter molecule for the quantification of pathogenic signatures 
during PCR amplification.33 The modification of TaqMan probes exhibit increased 
fluorescence intensity, with the hydrolysis of the fluorophore by Taq polymerase during 
PCR.33 The molecular beacon probe emits fluorescence as a result of hybridization to the 
complementary target of interest, causing a conformational change to the probe that allows 
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for increased fluorescence intensity.33 RT-PCR has been applied for the detection and 
quantification for O157:H7 and non-O157 STEC serogroups, in addition to the detection 
of STEC virulence genes (stx1, stx2, and eae).33-35  
Advantages to RT-PCR include the simultaneous detection and quantification of 
STEC pathogenic markers in a single tube reaction, leading to the elimination of post-PCR 
processing and a reduction in cross-contamination of PCR products.32-33  RT-PCR is a high 
throughout technique that allows for multiplex detection of genomic signatures, with 
multiple signatures tested simultaneously.32 RT-PCR is a highly sensitive technique that is 
considered 100-fold more sensitive than conventional end-point PCR.35 Potential 
disadvantages for real-time PCR include limitations to multiplex level, cost of reagents due 
to limited multiplex capability, and PCR primer incomaptibilty.29 Probe design 
considerations must also be taken into account when selecting fluorophores due to the 
overlap of emission spectra; therefore further complicating reconfiguration with the 
addition of genomic signatures and lending toward reduced signatures evaluated 
simulataneously.32 
1.8 MOL-PCR for STEC Detection 
 Multiplex oligonucleotide ligation-PCR (MOL-PCR) is a nucleic acid-based 
detection platform that can be used for the detection of O-serogroups and STEC-associated 
virulence factors (stx1, stx2, eae). Signal amplification is incorporated into  MOL-PCR 
assay chemistry that allows for the detection of unique signatures followed by 
amplification of the signal probe.29 Specifically, MOL-PCR incorporates multiplex ligation 
into the assay chemistry, which allows for ligation of oligonucleotide probes adjacent to 
each other in the presence of a complementary target sequence.29 MOL-PCR allows for 
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simultaneous detection of multiple nucleic acid signatures in a single tube reaction.29 In 
addition, MOL-PCR assay chemistry has been combined with microsphere arrays and flow 
cytometry for interrogation of pathogenic markers. Therefore, MOL-PCR is a high 
throughput technique that allows for the simultaneous detection of multiple nucleic acid 
signatures; including single nucleotide polymorphisms (SNPs), insertions, deletions, and 
repeats.36  
 The integration of multiplex ligation into MOL-PCR assay chemistry offers many 
advantages over target-based amplification. The addition of the ligation step allows for not 
only the detection of the target of interest, but allows for the characterization of the strain 
based on the detection of a SNP.36 ‘MOL-PCR also allows for a high degree of 
multiplexing due to the incorporation of multiplex ligation.29 The reconfiguration and 
expansion of the MOL-PCR assay is less cumbersome than other target-based 
amplification techniques.29 The addition of target detection probes pairs to the MOL-PCR 
assay usually has limited interaction with existing probes; therefore, reducing the time and 
cost of reconfiguration in comparison to RT-PCR or multiplex-PCR.29  
1.9 Previous Application of MOL-PCR for Detection of STEC-8 
 Molecular diagnostics that incorporate nucleic acid-based assays have been 
developed as diagnostic platforms for the detection of STEC. In particular, a high 
throughput MOL-PCR assay have been previously developed for the detection of STEC 
genomic signatures associated with human illness. The research in that study have been 
developed for the detection of 8-STEC serotypes (STEC-8) including; O26, O45, O103, 
O104, O111, O121, O145, O157:H7.37 In addition, the study can identify STEC associated 
virulence genes stx1, stx2, and eae. Published genomic sequences for the STEC-8 and 
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virulence genes were used to design target-specific probes for the detection of each unique 
signature.  
 The signatures for the detection of the STEC-8 and virulence genes was designed 
as an 11-plex MOL-PCR assay. This assay has the capability to identify each of the eight 
STEC serogroups and evaluates genomic signatures for the virulence genes (stx1, stx2, and 
eae).37 The signatures associated with the virulence genes allow for the discrimination 
between a STEC and a non-STEC strain. The assay successfully evaluated isolated 
genomic DNA from both commercial sources and STEC-CAP collaborators.37 The MOL-
PCR STEC-8 assay provided the basis for the research presented in this thesis. With the 
success of the STEC-8 assay, a detection and characterization assay that encompasses 
SNPs identified by Norman et al. have been developed for the identification of non-O157 
serogroups. The SNPs identified for each non-O157 serogroup are serogroup specific and 
are also unique to STEC strains.26 Therefore, the SNPs allow for detection of a serogroup 
and characterization of the strain with a single genomic marker without having to detect 
the serogroup and characterize the strain with multiple genomic markers.  
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Chapter 2: Motivation and Overview of the MOL-PCR SNP Based Assay 
 
 The motivation for this research is to develop a SNP based MOL-PCR assay for the 
detection of non-O157 STEC serogroups that have recently been declared as adulterants in 
raw non-intact beef.38 In 2012, the Food Safety and Inspection Service (FSIS) implemented 
mandatory testing for non-O157 STEC serogroups O26, O45, O103, O111, O121, and 
O145 (otherwise known as “big six” non-O157 serogroups).38 The SNP based MOL-PCR 
assay allows for further characterization of non-O157 isolates after initial screening.  The 
assay developed here is a high throughput, nucleic-acid based assay that utilizes MOL-
PCR assay chemistry for the detection of non-O157 serogroups. This assay improves upon 
the current STEC-8 MOL-PCR assay because it not only has the capacity to identify the 
targeted serogroup, but can differentiate between a STEC and non-STEC strain with the 
direct detection of a single nucleotide polymorphism.  
 Characterization of non-O157 isolates is important for mandatory testing of the 
non-O157 serogroups because not all non-O157 strains are considered pathogenic.17, 26 
E.coli strains that have been identified in cattle contain the same O-antigen as a STEC 
strain, yet not all strains contain the virulence genes that encode Shiga toxins.26 Therefore, 
the assay developed here can further characterize a non-O157 isolate by identifying the O-
serogroup and differentiating between strains that contain STEC-associated alleles. 
 The development of the MOL-PCR SNP based assay for the detection of non-O157 
serogroups is described in Chapter 3. The selection of DNA signatures for each of the non-
O157 serogroups were based on the SNPs identified by Norman et al.26 In their study, they 
used matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) genotyping 
to determine the frequency of STEC associated alleles for a panel of non-O157 STEC 
16 
 
strains.26  The MALDI-TOF assays were classified into three different classification groups 
based on the virulence profile (stx alone, stx with eae, stx with eae and ehxA).26 The three 
classification groups provided sensitivity and specificity estimates for the STEC allele to 
accurately detect the STEC strains associated with the virulence profiles.26 Sensitivity 
estimates refer to the proportion of strains that would result in a positive identification for 
producing the STEC-associated allele.26 The specificity estimates measured the proportion 
of strains that would produce a negative result and is indicative of a strain that is lacking 
the STEC-associated allele.26 Therefore, specificity estimates were used to correctly 
identify strains that do not contain the STEC-associated allele found in STEC strains.26 
Based on specificity and selectivity estimates, genes were selected for each of the six 
serogroups. Genes selected were used to computationally design PCR probes for both 
STEC and non-STEC signatures. 
 Two MOL-PCR SNP based assays have been designed for the detection of non-
O157 serogroups and their associated SNPs. Originally designed as a 14-plex detection 
assay for both STEC and non-STEC, the competition at the SNP site present on MOLigo2 
required the division of this assay into two detection assays. The STEC and non-STEC 
MOLigo pairs have been separated into two 8-plex probe panels, each containing an 
internal positive control. The sensitivity of the MOLigo pairs for both detection assays 
were evaluated against DNA panels provided by both collaborators and commercial 
sources. The 8-plex SNP based MOL-PCR assay correctly identifies the big six non-O157 
serogroups of interest. The non-STEC SNP assay was evaluated against known STEC 
strains to test the selectivity of the SNP against non-target samples. The assay demonstrates 
the ability to be highly specific when in the presence of multiplexed MOLigo pairs that 
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contain a single nucleotide base change. Here I demonstrate the development of two high 
throughput SNP based MOL-PCR assays for the detection and characterization of non-
O157 strains.  
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Chapter 3: Materials and Methods 
 
3.1. E.coli non-O157 Panel 
 Two bacterial strain panels were used for the development of the SNP based MOL-
PCR assay. The panel consisted of purified isolated genomic DNA for non-O157 
serogroups O26, O45, O103, O111, O121, and O145. The strains for each serogroup 
contained the STEC-associated allele and were identified as strains that contained the 
STEC-associated virulence genes. The strains were obtained from both commercial 
sources and collaborators. A training panel consisting of complementary synthetic target 
DNA for the O26 serogroup was also designed to evaluate specificity and sensitivity of the 
SNP when both STEC and non-STEC probes were evaluated in multiplex. 
3.2 SNP Selection  
 The selection of genomic signatures for this assay were designed from SNPs 
identified in a previous study.26 MOL-PCR assay chemistry consists of two MOLigo 
probes that are designed to anneal at the SNP discriminate site. To ensure the success of 
the MOL-PCR assay, SNPs were chosen based on sensitivity and specificity estimates 
provided by Norman et al.26 Categories for sensitivity and specificity estimates consisted 
of the SNPs identified for each serogroup, evaluated against strains that were positive for 
stx alone, stx with eae, and stx with both eae and ehxA.26 The O26 gene fnl1 contained a 
SNP that captured the O26 strains associated with stx1.26 Emergent strains for O26 have 
recently been found to contain the stx2 virulence gene.26 Therefore, the selection of two 
genes for O26 was necessary to capture strains that were positive for either stx1 or stx2.  
The gene wbhW 997 was initially selected for O45 based on the highest overall sensitivity 
and specificity estimates. After initial evaluation, O45 wbhW 997 was removed from the 
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probe panel due to cross reactivity between other MOLigo probes when evaluated in 
multiplex. O45 wbhQ 721 was selected to replace the gene O45 wbhW 997. O103 wbtD 
937 and O145 wzy 37 were the only SNPs identified for each serogroup and were selected 
by default. The selection of O111 wbdK 687 and O121 vioA 313 were selected based on 
the highest overall sensitivity and specificity estimates for each category. Norman et al. 
characterized the SNPs based on the gene, the base pair position within the gene, and the 
change in allelic discrimination.26 Table 3.1 lists the genes for the non-O157 serogroups 
that were selected for the design of oligonucleotide probes for the SNP based MOL-PCR 
assay. The referenced genome sequence for each gene appears in Appendix A.1-A.7.  
Table 3.1: List of non-O157 single nucleotide polymorphisms used in MOL-PCR assay  
Serogroup Gene Base Pair 
Position a 
Polymorphism b 
O26c fnl1 88 GA 
wzx 953 TG 
O45d wbhQ 721 CA 
O103e wbtD 937 CT 
O111f wbdK 687 CT 
O121g vioA 313 CT 
O145h wzy 37 AC 
a Location of the SNP within the gene 
b Non-STEC  STEC 
c GenBank AY763106 Reference Genome 
d GenBank AY771223 Reference Genome 
e GenBank AY532664 Reference Genome 
f GenBank AF078736 Reference Genome  
g GenBank AY208937 Reference Genome  
h GenBank AY647260 Reference Genome 
3.3 MOLigo Probe Design 
3.3.1 MOLigo Modular Components 
 The SNPs selected were used to computationally design highly specific single-
stranded oligonucleotide probes for the detection of non-O157 serogroups, otherwise 
known as MOLigo pairs (MOL-PCR oligonucleotide pairs). MOLigo pairs, designated 
20 
 
MOLigo1 and MOLigo2, are comprised of modular components that are 40-90 nucleotides 
long. The modular components main functions are 1) target sequence detection, 2) 
amplification of ligation products, and 3) hybridization of amplified products onto a 
microsphere array. MOLigo1 contains two functional modular components that consist of 
a sequence that is complementary to the 5’ dual biotinylated forward primer and a sequence 
that is complementary to the target sequence (Figure 3.1).  
 
Figure 3.1: Schematic for the composition of the modular components for MOLigo1 and MOLigo2. 
MOLigo2 for the STEC and non-STEC probe differ by both a single base on 3’ end and the anti-tag sequence. 
Depiction of two fluorescently labeled beads with 24-base capture sequence are used for discrimination 
between a STEC and non-STEC strain. Schematic adapted from Stucki et al.39  
MOLigo2 contains three modular components that consist of a sequence that is 
complementary to the universal reverse primer, a 24-base pair anti-tag sequence for bead 
capture of the amplified products onto a microsphere array, and a complementary target 
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sequence that contains the allelic discriminate (SNP) on the 3’ end of the probe (Figure 
3.1). 
3.3.2 MOLigoDesigner Tool 
MOLigo probe pairs for the biallelic SNP genomic marker selected for MOL-PCR 
were computationally designed using the MOLigoDesigner software developed at Los 
Alamos National Laboratory (https://moligodesigner.lanl.gov/MoligoDesigner/). MOLigo 
pairs for each serogroup were designed to be highly specific to the target of interest. 
Reference sequences provided by Norman et al. were used as input sequences for the 
MOLigo design tool (Appendix A.1-A.7).26 The input sequence consisted of the genomic 
sequence for each serogroup and the base pair position for the SNP for each non-O157 
gene selected. Default tags listed in the software were selected in conjunction with beads 
that were compatible with the MAGPIX® instrument. The default conditions and 
parameters programmed in the MOLigoDesigner software were used for designing each 
MOLigo pair.  
The MOLigoDesigner software provided two options for MOL-PCR assay 
chemistry; Classic MOL-PCR and Reverse MOL-PCR.40 The version of MOL-PCR assay 
chemistry selected for this assay was Reverse MOL-PCR. Reverse MOL-PCR differs in 
the design of modular components in comparison to Classic MOL-PCR.40 In Reverse 
MOL-PCR, the 24-base anti-tag sequence is located on MOLigo2 versus Classic MOL-
PCR that contains the complementary tag sequence on MOLigo1.40 Reverse MOL-PCR 
allows for greater flexibility when testing multiple alleles in a single tube reaction; 
furthermore, using a flow cytometer that has limitations in the number of fluorescent 
channels, such as the Luminex Magpix®.40 Table 3.2 and Table 3.3 list the MOLigo pairs 
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and primer sequences that were ordered from Integrated DNA Technologies 
(http://www.idtdna.com/) and used for experimental testing for both non-O157 assays.  
 
Table 3.2: List of MOLigo sequences for STEC non-O157 MOL-PCR assay.  
 
The forward primer, reverse primer, and 24-base anti-tag sequence are in bold, underlined, and italicized, 
respectively. The SNP discriminate is in bold and underlined. S denoted after the serogroup identifies the 
MOLigo that contains the STEC-associated allele. 
 
 
 
Serogroup xTAG SNP MOLigo Sequence (5’-3’) 
 
O26 S-
fnl1 
 
A042 
 
A 
M1 AAT ATC TGT ATC TAG AAA ACG CTT AAG TAC TCT CAC 
TTC TTA CTA CCG CG 
 
M2 ACT CGT AGG GAA TAA ACC GTA TTT GTT ATG ATA AAT 
GTG TAG TGA TCC CTG CTA AAT ATT CGT ATT TCA GT 
 
O26 S-
wzx 
 
A021 
 
G 
M1 CCC CCC CTA AAC TCA GGA CTC TCA CTT CTT ACT ACC 
GCG 
M2 ACT CGT AGG GAA TAA ACC GTA TTA AGT AAG AAT TGA 
GAG TTT GAG AAC CTT ATA TCC CAA TAT AGT ACC CC 
 
O45 S-
wbhQ 
 
A057 
 
A 
M1 CAG AAC ACG TGA GTC TAG CTT TGT CTC ACT TCT TAC 
TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTA GAG TAT TAG TAG TTA 
TTG TAA GTA GCA GAC AGA GTT CTG CGA T 
 
O103 S-
wbtD 
 
A012 
 
T 
M1 CAG GTT AAT ATT CTT ATT GTT ATT GAT TTT TTT TTC 
TCA CTT CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTA GTA GAA AGT TGA AAT 
TGA TTA TGA GAT ATT ATA TAT AAT TGC ATT TTA GAT 
TTA ATA TA 
 
O111 S-
wbdK 
 
A078 
 
T 
M1 CCT GTA ACC ATA TTC TCT TTT GGT AAA TTT CTC ACT 
TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTG TAT AGT GTG ATT AGA 
TTT GTA AAA CTC TTC GAA AAT ATC ATC ACT CTT AGT 
A 
 
O121 S-
vioA 
 
A063 
 
T 
M1 ATC AAT ATC GAC AAA AAC AGG TTT AAG CTC TCA CTT 
CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTT TTG TTG TTA AGT ATG 
TGA TTT AGT CGG ATC GAT ATT TAA GGT TTT GGA 
 
O145 S-
wzy 
 
A076 
 
C 
M1 CAC TCC ATT TAT AAA CTT ATC TTT CTT TAT ATT CAT 
CTC ACT TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTA AAG AAT TAG TAT GAT 
AGA TGA GAG TAA TAT AAC GAA GAA ATA ATT AAC CAA 
AAA AAA AG 
 
Ligation 
Control 
 
 
A056 
 M1 CTT TGG GGA TTA GCT CCG CTC TCA CTT CTT ACT ACC 
GCG 
 
M2 ACT CGT AGG GAA TAA ACC GTA ATT AGA AGT AAG TAG 
AGT TTA AGT GCA ATC CGA ACT GAG ATG GA 
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Table 3.3:  List of MOLigo sequences for non-STEC PCR assay.  
Serogroup xTAG SNP MOLigo Sequence (5’-3’) 
 
O26 NS-
fnl1 
 
A018 
 
G 
M1 AAT ATC TGT ATC TAG AAA ACG CTT AAG TAC TCT CAC 
TTC TTA CTA CCG CG 
M2 ACT CGT AGG GAA TAA ACC GTG TAA TTG AAT TGA AAG 
ATA AGT GTC CCT GCT AAA TAT TCG TAT TTC AGC 
 
O26 NS-
wzx 
 
A014 
 
T 
M1 CCC CCC CTA AAC TCA GGA CTC TCA CTT CTT ACT ACC 
GCG 
M2 ACT CGT AGG GAA TAA ACC GTA TTG TGA AAG AAA GAG 
AAG AAA TTG AAC CTT ATA TCC CAA TAT AGT ACC CA 
 
O45 NS-
wbhQ 
 
A051 
 
C 
M1 CAG AAC ACG TGA GTC TAG CTT TGT CTC ACT TCT TAC 
TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTG ATA AGA AAG TGA AAT 
GTA AAT TGA GCA GAC AGA GTT CTG CGA G 
 
O103 NS-
wbtD 
 
A073 
 
C 
M1 CAG GTT AAT ATT CTT ATT GTT ATT GAT TTT TTT TTC 
TCA CTT CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTG TTG AGA ATT AGA ATT 
TGA TAA AGC AAG TTT AGA TAT TAT ATA TAA TTG CAT 
TTT AGA TTT AAT ATG 
 
O111 NS-
wbdK 
 
 
A026 
 
C 
M1 CCT GTA ACC ATA TTC TCT TTT GGT AAA TTT CTC ACT 
TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTT TTG ATT TAA GAG TGT 
TGA ATG TAC TCT TCG AAA ATA TCA TCA CTC TTA GTG 
 
O121 NS-
vioA 
 
A053 
 
C 
M1 ATC AAT ATC GAC AAA AAC AGG TTT AAG CTC TCA CTT 
CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTG TTT GTG TTT GTA TAA 
GTT GTT AAT CGG ATC GAT ATT TAA GGT TTT GGG 
 
O145 NS-
wzy 
 
A055 
 
A 
M1 CAC TCC ATT TAT AAA CTT ATC TTT CTT TAT ATT CAT 
CTC ACT TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTG AAG ATA TTG AAA GAA 
TTT GAT GTA GTA ATA TAA CGA AGA AAT AAT TAA CCA 
AAA AAA AAT 
 
Ligation 
Control 
 
 
A056 
 M1 CTT TGG GGA TTA GCT CCG CTC TCA CTT CTT ACT ACC 
GCG 
 
M2 ACT CGT AGG GAA TAA ACC GTA ATT AGA AGT AAG TAG 
AGT TTA AGT GCA ATC CGA ACT GAG ATG GA 
 
The forward primer, reverse primer, and 24-base anti-tag sequence are in bold, underlined, and italicized, 
respectively. The SNP discriminate is in bold and underlined. NS denoted after the serogroup identifies the 
MOLigo that contains the non-STEC associated allele. 
 
 
 3.4 MOL-PCR Assay 
 MOL-PCR is a nucleic-acid based diagnostic platform that allows for simultaneous 
detection of multiple genomic signatures.29, 36 MOL-PCR assay chemistry incorporates 
multiplex ligation that allows of detection of multiple targets in a single reaction.29-36 I have 
adapted and modified MOL-PCR assay chemistry by separating the ligation and PCR 
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reaction into two separate reactions. The MOL-PCR assay consists of the following steps 
(Figure 3.2): 
1. MOL-PCR is comprised of single-stranded oligonucleotide probes that are 
designated as MOLigo pairs (MOL-PCR oligonucleotide pairs). MOLigo1 and 
MOLigo2 anneal adjacent to each other at the SNP discrimination site in the 
presence of a complementary target sequence. Thermostable DNA ligase 
covalently links MOLigo1 and MOLigo2 together, creating a single stranded DNA 
molecule that is 100-150 nucleotides in length. The MOLigo1+MOLigo2 complex 
serves as the template for singleplex PCR amplification. The ligation of MOLigo1 
and MOLigo2 serves as the target detection event, with DNA ligase binding the 
MOLigo pairs only in the presence of a complementary target sequence.  
2. The ligation product proceeds with singleplex PCR amplification with a set of 
universal primer pairs. MOLigos that did not anneal adjacent to one another will 
produce asymmetric amplified PCR products because the forward primer and 
reverse primer remain on separate MOLigo pairs. Ligated MOLigos contain 
modular components that are complementary to the universal forward and reverse 
primer sequences. The universal forward primer is composed of a 5’ dual 
biotinylated moiety that serves as the binding site for the reporter molecule 
Streptavidin-R-phycoerythrin (SAPE).  
3. The amplified ligation products are hybridized to a Luminex xTAG® microsphere 
array using xTAG® sequences that are complementary to anti-tag sequence on 
MOLigo2. Luminex xTAG® microspheres are color coded microspheres and 
contain a 24-base capture sequence that is covalently attached to a polystyrene 
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microsphere. The bead PCR-products are incubated with SAPE forming the biotin-
streptavidin complex that allows for production of fluorescence during signal 
detection on a Luminex platform. The hybridized product is analyzed by flow 
cytometer that measures fluorescence intensity emitted by the labeled PCR product.  
3.5 MOL-PCR Protocol 
 STEC and non-STEC MOLigos were divided into two separate assays for the 
interrogation of the non-O157 SNPs. Potential competition at the SNP discriminatory site 
required the division of the designed 15-plex assay into two 8-plex assays. Each 8-plex 
assay consisted of 16 MOLigo probes and 8 MagPlex-xTAG® microspheres. The assay 
includes three controls; an internal positive control for ligation, a full length PCR 
amplification control, and a no template PCR control to evaluate cross reactivity in the 
absence of a DNA template. The MOL-PCR protocol is divided into four steps:  
1. Annealing and Ligation of MOLigo Pairs: The ligation reaction was performed 
in a final reaction of 20 µL containing 1.25 units of Ampligase® Thermostable 
DNA Ligase (Epicentre), 1x Ampligase® reaction buffer (Epicentre), 2 nM of each 
MOLigo probe (Integrated DNA Technologies (IDT)), 1.25 units of Uracil-DNA  
Glycosylase (UDG) (ThermoFisher Scientific), 1.5 mg/mL Salmon Sperm DNA 
(ThermoFisher Scientific) and 2 µL of template DNA. The thermal cycling profile 
for the ligation reaction includes UDG treatment to prevent PCR carry-over 
contamination at 37°C for 30 minutes, DNA denaturation at 95°C for 3 minutes, 30 
ligation cycles of 95°C for 25 seconds and 58°C for 2 minutes, UDG inactivation 
at 95°C for 30 minutes, and hold at 4°C until further processing.  
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Figure 3.2: Schematic for MOL-PCR. 1) MOLigo pairs anneal adjacent to each other at the SNP discriminate 
site. DNA ligase recognizes the structure and covalently links MOLigo1 to MOLigo2, creating single 
stranded DNA molecule. 2) Ligated product proceeds through PCR amplification with biotinylated forward 
primer. 3) Amplified ligation product is hybridized to Luminex xTAG microsphere via 24-base anti-tag 
sequence. Bead-PCR complex is analyzed on Luminex platform. Schematic adapted from Stucki et al.39  
 
2. PCR Amplification of PCR Product: The PCR reaction was performed in a final 
reaction of 20 µL containing GenAmp® 1X PCR Buffer II (ThermoFisher 
Scientific), 4 mM of MgCl2 (ThermoFisher Scientific), 0.05 U of AmpliTaq Gold® 
DNA polymerase (ThermoFisher Scientific), dNTP/dUTP mix composed of 200 
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µM each of dATP, dCTP, dGTP and 400 µM dUTP (ThermoFisher Scientific), 0.5 
µM of 5’ dual biotinylated forward primer (IDT) (Table 3.4),0.1 µM reverse primer 
(IDT)(Table 3.4), and 2 µL of the ligation product was added to the PCR master 
mix. The thermal cycling profile for PCR reaction is as follows; 95°C for 10 
minutes, 45 cycles of 95°C for 15 seconds, 58°C for 20 seconds, 72°C seconds, and 
a final extension at 72°C for 7 minutes. The reaction were held at 4°C until 
proceeding with the bead-hybridization step. 
Table 3.4: Forward and Reverse Primer Sequences 
 
Forward Primer 
 
/52-Bio/CGC GGT AGT AAG AAG TGA GA 
 
Reverse Primer ACT CGT AGG GAA TAA ACC GT 
 
3. Hybridization of beads: The microsphere mixture was prepared using anti-tag 
Luminex xTAG® microspheres for each MOLigo pair that was being interrogated. 
Each bead mix contained 8 MagPlex x-TAG® microspheres (Luminex 
Corporation) for both the STEC and non-STEC assay. The bead mixture contained 
2500 microspheres of each bead per reaction and was stored in 800 mM NaCl and 
50 mM MES (Sigma Aldrich). For the hybridization reaction, 10 µL of bead 
mixture was added to the MOL-PCR reaction. The thermal cycling conditions 
include; 95°C for 3 minutes, a slow ramp down decreasing in temperature to 50°C 
in 10°C increments with a hold for 1 minute, 50°C for 30 minutes, and a ramp down 
decreasing in temperature to 25°C by 5°C increments. The reaction was held at 4°C 
for further processing.  
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4. Labeling of PCR product and Analysis on Luminex Platform: The bead-PCR 
product proceeded through a wash step before being labeled with SAPE. The wash 
step consists of separation of the supernatant from the bead-PCR product using a 
magnetic separator (EMD Millipore) for 5 minutes. SAPE is prepared at 10 ug/mL 
(BD Bioscience) in 1x TE Buffer (Affymetrix). The addition of 25 µL of SAPE is 
added to each reaction and incubated for 30 minutes. The labeled bead-PCR 
complex is washed to remove excess SAPE and re-suspended in 100uL of 1x TE 
Buffer (Affymetrix). The reaction is transferred into a 96-well v-bottom plate for 
the interrogation on the Luminex MagPix® (EMD Millipore).  
3.6 Wilcoxon Rank Sum Test for SNP calling  
The test samples and the control samples (no template control, ligation control, and 
PCR control) were interrogated using the Luminex MagPix®. Median fluorescence 
intensity (MFI) values were used in conjunction with the Wilcoxon rank sum test for 
statistical analysis. MFI values were based on the collection of 100 beads per region in 
each sample set. The Wilcoxon rank sum test is non-parametric statistical analysis tool that 
allows for the comparison of two samples that are either independent or unrelated. 41 The 
statistical analysis algorithm was developed by Woods et al. for the analysis of STEC 
samples using MOL-PCR assay chemistry.37 The MFI values for the no template control 
and the test samples were combined and ranked in ascending order. The sum of the ranks 
were computed for both the test samples (WA) and the no template control(WB). 
Determination of the p-value for the Wilcoxon rank sum statistic was calculated by 
determining the distribution of the ranked sums (μA), the standard deviation (σA), and the 
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z-score (z).  The sum of the ranks computed for the test samples (WA) were used to 
calculate the z-score. 
μA =
n1(n1 + n2 + 1)
2
 
σA = √
n1n2((n1 + n2 + 1)
12
 
z =
(WA − 0.5) − μA
σA
 
The approximate and exact Wilcoxon rank sum test were used for identification of 
the test samples. The approximate Wilcoxon rank sum test compared the p-value to the 
statistical significance level(α = 0.01). P-values greater than α= 0.01 resulted in a positive 
identification for the serogroup and P-values less than α= 0.01 resulted in a negative 
identification for the serogroup.  
P-value > 0.01=Positive 
P-value < 0.01=Negative 
The exact Wilcoxon rank sum test compared the sum of ranks for the test samples 
(WA) to the critical value. A one-tailed z-test and a statistical significance level of 0.05 was 
used for the exact Wilcoxon rank sum test.  The critical values correspond to the statistical 
significance level and are listed in Appendix B. The critical value that were greater than 
WA resulted in a negative call for the serogroup. If the critical value is less than WA, the 
test sample resulted in a positive call for the serogroup.  
Critical Value < WA =Positive 
Critical Value > WA=Negative 
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Chapter 4: Results and Discussion 
4.1 MOLigo Probe Selection and Assay Design 
The MOL-PCR assay in this study evaluated 14 genomic markers for STEC and 
non-STEC; in addition to an internal ligation control and a PCR control. MOLigo pairs 
were designed for the biallelic SNP associated with each non-O157 serogroup. The MOL-
PCR assay was originally designed as a 15-plex assay that consisted of MOLigo pairs for 
each biallelic SNP and an internal ligation control. Due to competition at the SNP 
discriminate site, the MOL-PCR 15-plex assay was divided into two 8-plex assays that 
evaluated the STEC and non-STEC associated alleles separately. MOLigo1 was identical 
for both biallelic SNPs, with MOLigo2 differing by both the SNP discriminate located on 
3’ end and the anti-tag sequence.  
The selectivity for each biallelic SNP was associated with sensitivity and specificity 
estimates provided by Norman et al.26 Estimates for each SNP were based on the capacity 
for the SNP to identify strains that contained stx alone, stx with eae, and stx with eae and 
ehxA.26 Therefore, the SNPs for each serogroup were selected based on the highest 
sensitivity and specificity estimates for each category. SNPs for each non-O157 serogroup 
were evaluated in singleplex and multiplex format to determine overall performance of 
each SNP. The SNP selected for O45 wbhW 997 contained the highest overall sensitivity 
and specificity estimates for each category, yet underperformed in singleplex and exhibited 
cross reactivity in multiplex. The MOLigo pair for O45 wbhW 997 was not included in the 
test panel. The SNP for O45 wbhQ 721 contained the next overall highest sensitivity and 
specificity estimates for each category and was chosen to be evaluated in the probe panel. 
O45 wbhQ 721 increased in performance and cross-reactivity was eliminated upon the 
incorporation of this MOLigo pair into the probe panel.   
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4.2 Assay Development with Training Panel 
 The original MOL-PCR protocol included ligation and amplification in a single 
tube reaction.36 The SNP based MOL-PCR protocol separated the ligation and 
amplification reactions to improve assay performance. The STEC and non-STEC MOL-
PCR assays were originally evaluated as a 2-plex (O26 fnl1 and wzx) against a training 
panel consisting of complementary synthetic target sequences (Appendix C). The training 
panel was used to optimize the ligation and PCR conditions for both MOL-PCR assays, as 
a result of poor signal-to-noise ratios when initially evaluating the assays against STEC 
DNA samples. The objective of this experiment was to evaluate the specificity of the 
MOLigo pairs to their intended target when evaluated in multiplex format. A ligation 
control was incorporated into this assay to ensure that the ligation reaction was performing. 
The assay was evaluated in quadruplicate for both samples and ligation controls.  
Table 4.1 shows the ability for the O26 MOLigo pairs designed for both the STEC 
and non-STEC assays to correctly identify their synthetic complementary targets. The MFI 
values for this assay exhibit inconsistencies between replicates that may be attributed to 
issues with transferring the ligation product to the amplification reaction. The O26 STEC 
wzx MOLigo pair identifies the complementary target in the first and the fourth replicate, 
with second and third replicates failing to identify the target. The O26 STEC fnl1 MOLigo 
identifies the complementary target in each replicate. The fourth replicate for O26 STEC 
fnl1 exhibits cross reactivity between O26 STEC fnl1 and wzx genes that may be the result 
of cross-reactivity between samples. The non-STEC MOLigos for both genes correctly 
identify each of their intended targets. Overall, the experiment shows the ability for each 
MOLigo pair to identify their complementary synthetic target when evaluated in multiplex.  
Further optimization of the assay is required to improve inconsistencies between replicates. 
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Table 4.1: Synthetic target sequences were designed for assay development. Both STEC and non-STEC 
synthetic target sequences were designed for O26 genes wzx and fnl1. The STEC and non-STEC MOLigos 
were evaluated separately, consisting of the interrogation of the assay in multiplex (2-plex). The MOLigo 
pairs accurately identify their respective targets. 
4.3 MOLigo Pairs Evaluated in Singleplex 
The STEC non-O157 assay was evaluated as a singleplex assay to determine 
specificity of the MOLigo pairs to their intended targets.  In this experiment, MOLigo pairs 
containing the STEC-associated allele were evaluated in singleplex by running multiple 
MOL-PCR assays in parallel. The probe panel consisted of purified genomic DNA for each 
non-O157 serogroup (Appendix D.1). The objective of this experiment was to evaluate the 
specificity of the STEC MOLigo pairs against their intended target in the absence of the 
other non-O157 MOLigo pairs.  
 The results in Table 4.2 show the ability for each STEC non-O157 MOLigo pair 
to correctly identify their intended target. The MFI values for O26 wzx and O45 wbhW 
identified the sample correctly, yet the MFI values are considerably lower than the other 
STEC non-O157 MOLigos. The virulence profile identified for BAA-2196 indicate the 
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strain is O26 positive and contains both stx1 and stx2 (Appendix D.1). The MOLigo pair 
for wzx correctly identifies the target sequence, unfortunately the signal-to-noise ratio is 
only slightly higher than the background. In subsequent experiments, O45 wbhW was 
eliminated from the MOLigo probe panel and replaced with O45 wbhQ due to poor 
MOLigo performance. This study provides insight as to how each MOLigo pair was 
performing for the STEC non-O157 serogroups. The range of MFI values between each 
samples is highly variable and could be a result in the variation of the bead counts 
associated with each MOLigo pair. The non-STEC assay was not evaluated in singleplex, 
due to absence of non-STEC strains.  
 
Table 4.2: STEC MOLigo pairs evaluated in singleplex format. Experiment designed to evaluate MOLigo 
pair specificity for each non-O157 serogroup.  
4.4 STEC non-O157 Assay Evaluated in Multiplex 
 The STEC non-O157 assay was evaluated as an 8-plex that consisted of the 
MOLigo pairs containing the seven STEC-associated alleles and an internal ligation 
control. The internal ligation control was incorporated into the assay to ensure the ligation 
reactions were working proficiently. A set of MOLigo pairs were designed for the ligation 
control to target a complementary synthetic oligonucleotide strand. The STEC MOLigo 
pairs designed for each assay were evaluated against an E.coli DNA panel that consisted 
of 6 known STEC strains. The validation of the 8-plex STEC assay examined each serotype 
identified in Appendix D.2 in triplicate.  
34 
 
Initial testing for the STEC non-O157 MOL-PCR assay is presented in Table 4.3. 
The PCR protocol initially included deoxythymidine triphosphate (dTTPs) incorporated 
into the dNTP mix for the PCR reaction. The MOLigo pair for O26 wzx identifies each 
strain as a positive for O26 wzx. This is a result of MOLigo probe contamination with the 
synthetic complementary target for O26 wzx. This assay also exhibits cross reactivity for 
strain CDC 96-3285 for each non-O157 MOLigo pair. The SNP for O45 wbhW was located 
near the end of the gene; therefore, the MOLigo pair designed was intergenic which may 
have contributed to the cross-reactivity seen in this experiment. Based on this experiment, 
O45 wbhW was redesigned and replaced with O45 wbhQ. Besides the synthetic target 
contamination, each of the STEC non-O157 MOLigo pairs correctly identify their intended 
targets. Due to the contamination, MOLigo pairs were redesigned and reordered for 
subsequent experiments and incorporation of UDG and deoxyuridine triphosphate (dUTPs) 
were added to reduce PCR contamination (Appendix E: Original MOLigo Design). 
 
Table 4.3: Initial testing for STEC non-O157 8-plex assay evaluated against DNA STEC panel.  
MOLigo pairs were redesigned for O26 wzx, O103 wbtD, O111 wbdK, and O145 
wzy to incorporate anti-tag sequences for Luminex xTAG® microspheres that were 
associated with the Luminex MagPix®. The PCR protocol was changed to replace dTTPs 
with dUTPs, to reduce carry-over PCR contamination (described in Appendix F). The 
STEC non-O157 assay was evaluated in multiplex against a STEC DNA panel from the 
STEC CAP collaborators. The STEC MOLigos were assembled into an 8-plex that 
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included the seven MOLigo pairs for the non-O157 serogroups and an internal control. A 
full length O26 oligonucleotide sequence was also included to evaluate PCR efficiency. 
The ligation and PCR reaction were performed in a 10 µL reaction. 
Table 4.4 shows the results for the newly designed MOLigo pairs and the 
incorporation of both UDG and dUTPs into both the ligation and PCR reactions. The MFI 
value for the O103 MOLigo pair was considerably lower in comparison to the other STEC 
MOLigo pairs. This may be attributed to the addition of dUTPs in the PCR reaction to 
combat PCR carry-over contamination. The O103 MOLigo pair evaluated in singleplex 
and the initial evaluation of the 8-plex assay consisted of dTTPs in the PCR reaction and 
performed substantially better than the reactions that included dUTPs (Table 4.2 and Table 
4.3). The assay exhibits cross-reactivity when evaluating the strains JB1-95, CDC 97-3068, 
and 83-75. This is the result of cross-reactivity between samples and is not indicative of 
cross-reactivity between MOLigo pairs. The negative strand for the O103 MOLigo pair is 
currently undergoing optimization to possibly replace the current positive strand for the 
O103 MOLigo pair. 
 
Table 4.4:  Results for the STEC MOL-PCR assay evaluated against STEC DNA panel. The results of the 
8-plex STEC MOL-PCR assay evaluated against known STEC strains. The results included here are 
indicative of single replicates that made correct calls for a single sample set.  
Optimization of the reaction has continued with the evaluation of the assay in a 20 
µL reaction. The assay was exhibiting inconsistencies between sample replicates and the 
no template control. Inconsistencies between replicates for the 10 µL reaction is most likely 
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associated with evaporation during ligation and PCR reactions. Table 4.5 shows the initial 
evaluation of the 20 µL reaction. Increasing the reaction volume increased the MFI values 
for O103 wbtD in this reaction. The MOLigos correctly identify each of their intended 
targets. This experiment shows cross-reactivity across each sample, with the exception of 
the ligation and PCR control. The spurious amplification between samples is believed to 
be contributed to sample transfer either from ligation to amplification reactions or possibly 
aerosol contamination when adding xTAG® microspheres to the hybridization reaction. 
The ligation control is positive in samples JB1-95, CDC 97-3068, and 83-75 that may also 
be a result of cross-reactivity between wells since it is not seen in the first three samples. 
Separating the ligation and amplification reactions creates an open system that opens many 
avenues to potential contamination.  
 
Table 4.5: STEC MOL-PCR assay evaluated in a 20 µL reaction against STEC DNA panel.  
4.5 non-STEC Multiplex Assay 
The non-STEC assay was evaluated as an 8-plex that consisted of the MOLigo pairs 
containing the non-STEC associated alleles and an internal ligation control. The non-STEC 
assay was examined against STEC samples provided by collaborators (Appendix D.2). The 
purpose of this experiment was to evaluate the specificity of the SNP identified for each 
non-O157 serogroup. Specificity estimates were defined by Norman et al. as the probability 
for the non-STEC associated allele to be unable to detect the STEC-associated allele.26 To 
determine specificity of the non-STEC associated allele, the non-STEC MOLigo pairs were 
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evaluated against strains that contained the STEC-associated alleles. The internal ligation 
and PCR controls were included in this reaction. The ligation control consists of a set of 
MOLigo pairs that proceed through the ligation reaction, and are indicative that the ligation 
reaction is working. The full length O26 PCR control is a single stranded oligonucleotide 
that proceeds through amplification and serves as control to determine PCR efficiency. 
Therefore, the 8-plex non-STEC MOL-PCR was evaluated to determine both the 
specificity of the SNP and how efficiently the MOL-PCR assay chemistry could 
discriminate against the STEC-associated allele. 
Table 4.6 shows the results for the non-O157 specificity experiment. The ligation 
control and the full length O26 PCR control exhibited high signal-to-noise ratios and were 
indicative of both the ligation and PCR reactions working accordingly. The non-STEC 
MOL-PCR assay did not identify the STEC strains, indicating high specificity for the SNP 
associated with non-STEC serogroups.  The results in Table 4.6 show the ability for the 
non-STEC MOLigo pairs to accurately discriminate against the STEC-associated alleles. 
Therefore, the MOL-PCR assay chemistry has the ability to accurately discriminate 
between strains that differ by a single base change. To ensure the non-STEC MOLigo pairs 
are performing optimally, the non-STEC assay will need to be evaluated against non-STEC 
strains.  
 
Table 4 6: Results for non-STEC SNP specificity assay evaluated against known STEC targets. The non-
STEC MOL-PCR assay was evaluated against STEC strains. The results confirm specificity estimates for 
the non-STEC MOLigos to discriminate against the STEC-associated allele. The ligation and PCR control 
were included to confirm the reaction was performing optimally.  
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Chapter 5: Summary of Work and Future Directions 
5.1 Summary of Work 
Non-O157 STEC strains associated with human illness have increased in frequency 
and are considered a causative agent for hemorrhagic colitis and hemolytic uremic 
syndrome.3 Determining the prevalence for non-O157 STEC strains associated with human 
illness is limited due to the absence of mandatory characterization of isolates and diagnostic 
tools that can detect and characterize non-O157 strains.26 With the implementation of 
mandatory testing for O26, O45, O103, O111, O121, and O145, single nucleotide 
polymorphisms have been identified for each serogroup that can discriminate between a 
STEC and a non-STEC strain.26 To overcome limitations of current diagnostic methods, a 
nucleic acid-based detection platform that incorporates the SNPs recently identified was 
successfully designed for the detection and characterization of non-O157 strains. 
5.1.1 Development of MOL-PCR SNP Based Detection Assay 
 In this study, a high throughput MOL-PCR SNP based assay was successfully 
designed to detect and characterize non-O157 strains. The MOL-PCR SNP based assay 
offers improvement over conventional non-O157 PCR detection systems by incorporating 
SNPs into the MOLigo target detection probes. The SNPs are serogroup specific and can 
differentiate between a STEC and non-STEC strain. Therefore, eliminating the need for 
multiple target detection probes to detect the O-serogroup and virulence genes.  
The computationally designed MOLigo pairs were able to accurately identify the 
O-serogroup and characterize the strain based on the STEC-associated alleles. STEC and 
non-STEC MOLigo pairs for O26 genes fnl1 and wzx, were initially evaluated against 
synthetic complementary target sequences. Synthetic complementary target sequences 
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were designed to determine ligation and PCR conditions due to poor signal-to-noise ratios 
when evaluated against a STEC DNA panel. The O26 MOLigo pairs have demonstrated 
the capacity to accurately identify their complementary synthetic targets. 
The STEC non-O157 assay was successfully developed and tested in both 
singleplex and multiplex format. In Chapter 4, the STEC non-O157 MOLigo pairs 
accurately identify each target when evaluated in singleplex. The singleplex assay 
determined which MOLigo pairs were under performing and provided insight as to which 
MOLigo pairs would need to be redesigned. Furthermore, the STEC non-O157 assay was 
evaluated as an 8-plex, consisting of MOLigo pairs for the 7 STEC-associated alleles 
identified for the non-O157 serogroups and an internal ligation control. The 8-plex assay 
identified each strain in the STEC DNA panel, yet the assay exhibited cross-reactivity 
between samples. Also, the MFI values for the O103 MOLigo pair are substantially lower 
than the other MOLigo pairs interrogated. The SNP identified for O103 is unfortunately 
the only SNP identified for this particular serogroup and could not be redesigned. To 
improve signal-to-noise ratios for O103, a titration of concentrations would need to be 
performed to determine if increasing the concentration of O103 MOLigo will increase the 
performance of this MOLigo pair. The STEC non-O157 assay is not performing 
consistently and further optimization and validation is needed.  
The non-STEC assay was evaluated against known STEC strains. The assay was 
evaluated as an 8-plex that included the MOLigo pairs containing the non-STEC associated 
allele and an internal ligation control. The objective of this experiment was to test the 
specificity of the non-STEC MOLigo pairs against STEC strains. This experiment was 
performed to ensure that the non-STEC MOLigos were not producing false positives when 
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evaluated against a strain that differed by a single base. Therefore, the non-STEC MOLigos 
were evaluated against known STEC strains to determine both the specificity of the non-
STEC associated allele and also to determine if the MOL-PCR assay chemistry was 
accurately discriminating against the STEC associated allele. The non-STEC MOLigo 
pairs accurately discriminate against the STEC-associated allele; in addition, this 
experiment provided further confidence in the ability for the MOL-PCR assay chemistry 
to accurately differentiate between strains that differ by a single base change. The non-
STEC assay was not evaluated against non-STEC strains; thus, it cannot be confirmed from 
this study that the assay can correctly identify the non-O157 serogroups for a non-STEC 
strain. 
5.2 Future Directions  
 The work presented in this thesis provides a potential diagnostic platform that can 
accurately detect and characterize non-O157 strains. The design and initial testing provide 
the framework for future validation of the SNP based MOL-PCR assays. The assays 
developed here can contribute to better understanding of true prevalence estimates for non-
O157 strains in cattle and raw non-intact beef. Summarized in this section are future 
potential directions that will contribute to the overall improvement of the MOL-PCR assay.  
5.2.1 Optimization of the STEC non-O157 Assay 
 Although the STEC non-O157 assay has the ability to correctly identify each of 
their intended targets, further optimization of reaction conditions is necessary. The negative 
strand for the O103 MOLigo pair is underperforming upon the incorporation of dUTPs.  
The O103 MOLigo pair contains a homopolymer of 9 thymines located on MOLigo1 and 
it appears that the assay may be experiencing PCR inefficiency with the present 
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concentration of the dNTP/dUTP mix. A solution to this problem would be to purchase 
dNTPs in a solution set rather than a mix, and possibly increase the concentration of dATPs 
to see if the signal-to-noise ratios will increase for O103. The positive strand for O103 has 
been evaluated for the O103 MOLigo pair; unfortunately, the strand has not shown 
improvement over the negative strand. The last option would be to incorporate dTTPs back 
into the PCR reaction, which the assay has previously worked during initial evaluation of 
the singleplex and the 8-plex assays. Stringent standard operation procedures would have 
to be followed to prevent PCR contamination (Appendix G).  Table 5.1 shows the effect of 
the incorporation of dUTPs into the MOL-PCR SNP based assay. Furthermore, 
reproducibility between replicates and between operators was found to be poor. 
Determining optimal ligation and PCR conditions should reduce inconsistencies between 
sample replicates. 
A) 7-plex with dTTPs in PCR reaction
 
B) 8-plex with dUTPs in PCR reaction 
 
Table 5.1: A) Assay evaluated as a 7-plex with the ligation control separated from the non-O157 MOLigos. 
The PCR reaction included dTTPs and also included the O45 wbhW gene before redesigning. O45 wbhw 
exhibits cross reactivity and was redesigned in subsequent experiments. B) The assay was evaluated as an 
8-plex assay. The PCR reaction incorporates dUTPs into the reaction and shows a drastic reduction in 
signal for O103 wbtD. The O26 S-wzx MOLigo was positive in each sample for both assays due to 
synthetic O26 wzx DNA contamination.  
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5.2.2 Validation of STEC non-O157 Assay  
 Once the optimization for the STEC non-O157 has been achieved, validation of the 
STEC non-O157 assay will need to be assessed to determine robustness of the assay. 
Currently, the 8-plex STEC assay has only been evaluated against 6 STEC strains. This 
assay will need to be validated against a STEC DNA panel that consists of 220 samples 
from ATCC, Kansas State University (KSU), University of Nebraska-Lincoln (UNL), and 
the United States Department of Agriculture (USDA). An exclusivity panel consisting of 
20 organisms that are distantly related to non-O157 strains will also need to be included to 
determine selectivity estimates for this assay.  Moreover, the limit of detection (LOD) will 
need to be determined to better understand the minimum amount of nucleic acid copies that 
can be detected for this assay. With the validation of this assay and the determination of 
the LOD, the next step will be to evaluate the STEC MOL-PCR assay against spiked fecal 
samples provided by KSU. These particular samples will allow us to test the STEC MOL-
PCR assay against complex samples that would mimic samples found in a clinical 
laboratory setting.  
5.2.3 Optimization and Validation of the non-STEC Assay 
 The non-STEC MOL-PCR assay was evaluated against 6 known STEC strains. To 
determine if the assay is working optimally, the assay will need to be evaluated against 
non-STEC strains. The USDA is providing us with 13 non-STEC E.coli strains. The non-
STEC MOLigo pairs for each serogroup will be evaluated against the E.coli strains 
provided to determine the specificity of the MOLigo pairs to their intended targets. This 
experiment will determine if the assay is optimized or if further optimization is needed. 
The strains provided will also allow us to determine LOD for the non-STEC assay.  
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5.2.4 MOL-PCR Incorporating Dual-Priming Oligonucleotides (DPO) 
 MOL-PCR assay chemistry offers numerous advantages over conventional and 
real-time PCR technologies. A potential future direction that could help overcome cross-
reactivity and increase allelic discrimination for the STEC and non-STEC assays is the 
incorporation of a dual priming oligonucleotide system. This provides a unique 
modification to MOL-PCR assay chemistry that has been explored in previous studies for 
the interrogation of SNPs.43 The introduction of the DPO system is incorporated into 
MOLigo2 containing the SNP discriminate and is designed to increase allelic specificity.43 
The DPO system separates MOLigo2 into two primer segments that are joined together by 
a polydeoxyinosine [poly (I) linker], typically consisting of five deoxyinosine (I) bases  
(Figure 5.1).42 In comparison to the natural bases, deoxyinosine has a lower melting 
temperature and forms a “bubble-like” structure separating MOLigo2 into two distinct 
priming regions.42-43   
Figure 5.1: Modified modular components for MOL-PCR with integrated DPO system. Polydeoxyinosine 
linker incorporated into MOLigo2 design would reduce cross reactivity and increase allelic specificity.42 
MOLigo2 is separated into two components including; a 5’segment consisting of 11-23 nucleotides that 
allows for stable annealing and a 3’-segement consisting of 6-12 nucleotides that contains the SNP 
discriminate and determines target-specific extension.42  
The design of  MOLigo2 consists of a two separate regions; a 5’-segment (11-23 
nucleotides in length) that binds to the target DNA site for stable annealing and a 3’-
segment (6-12 nucleotides in length) that binds to the target DNA. Target-specific 
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extension will only occur if both segments of MOLigo2 bind to the target DNA; therefore, 
decreasing the extension of non-specific products and increase PCR specificity. This area 
of research is very interesting and would add to the increased specificity of the MOL-PCR 
SNP based assay. Also, the DPO system may allow for the STEC and non-STEC assay to 
be combined into a 15-plex assay that would contain the MOLigo pairs for both non-O157 
allelic discriminates and the internal ligation control. Therefore, eliminating the need to 
evaluate two assays separately and ultimately reducing the cost of reagents.  
5.2.5 Prevalence Studies of STEC non-O157 Associated with Cattle 
 Many outbreaks in the United States have been associated with beef products 
containing E.coli O157: H7.3, 17 Epidemiological studies have mainly focused on the 
prevalence of E.coli O157:H7, with limited understanding on true prevalence estimates for 
non-O157 serogroups.26 The development of the non-O157 MOL-PCR assay provides the 
framework for future prevalence studies of non-O157 STEC in cattle and raw non-intact 
beef. Better understanding of the prevalence of non-O157 STEC must be evaluated from 
pre-harvest to post-harvest.  
 Pre-harvest prevalence studies are important for decreasing non-O157 STEC 
strains in cattle feces and on cattle hides.44 Prevalence studies could include how 
interventions such as probiotics, vaccines, and antimicrobials effect fecal shedding of non-
O157 in feces.45 It would be interesting to understand how these interventions influence 
seasonal shedding, with summer months often contributing to an increase in prevalence 
rates of non-O157 STEC in feces.21 Cattle hides often test positive for O157:H7 and non-
O157 STEC and are a potential source for contaminating carcasses during slaughter. 21, 44 
The SNP based MOL-PCR assay could be used to better understand contaminants present 
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on hides, providing prevalence estimates for both STEC and non-STEC strains present on 
the cattle hides. 
 Post-harvest intervention are vital to ensure contaminated beef products are not 
distributed to the public. Highly variable prevalence estimates for non-O157 STEC are 
often reported consisting of rates between 2.1 to 70.1%.44 STEC contamination usually 
results from removal of the hide or the gastrointestinal tract.44 Many variables can influence 
prevalence rates including; STEC detection methods, pre-harvest intervention, and 
management practices.44  
The assay presented in this research could aid in estimation of true prevalence of 
non-O157 by accurately differentiating between a STEC and non-STEC strain. The work 
presented here provides the framework for future studies that could aid in the understanding 
of the prevalence estimates for non-O157 STEC strains and provide preventative measures 
to ensure the safety of the consumer.  
 
 
   
 
 
 
 
 
46 
 
References 
1. Bergan J, Lingelem ABD, Simm R, Skotland T, Sandvig K. Shiga toxins. Toxicon. 
2012;60(6):1085-107. 
 
2. Johannes L, Roemer W. Shiga toxins - from cell biology to biomedical applications. 
Nature Reviews Microbiology. 2010;8(2):105-16. 
 
3. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clinical Microbiology 
Reviews. 1998;11(1):142-+. 
 
4. Fagerquist CK, Sultan O. Top-Down Proteomic Identification of Furin-Cleaved 
alpha-Subunit of Shiga Toxin 2 from Escherichia coli O157:H7 Using MALDI-
TOF-TOF-MS/MS. Journal of Biomedicine and Biotechnology. 2010. 
 
5. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, O'Brien 
AD, et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157 : H7. 
Journal of Biological Chemistry. 2004;279(26):27511-7. 
 
6. Garred O, Dubinina E, Polesskaya A, Olsnes S, Kozlov J, Sandvig K. Role of the 
disulfide bond in Shiga toxin A-chain for toxin entry into cells. Journal of 
Biological Chemistry. 1997;272(17):11414-9. 
 
7. Garred O, Vandeurs B, Sandvig K. Furin-Induced Cleavage and Activation of 
Shiga Toxin. Journal of Biological Chemistry. 1995;270(18):10817-21. 
 
8. Fraser ME, Chernaia MM, Kozlov YV, James MNG. Crytsal-Structure of the 
Holotoxin From Shigella-Dysenteriae at 2.5-Angstrom Resolution. Nature 
Structural Biology. 1994;1(1):59-64. 
 
9. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, et al. 
1BOS: Shiga-Like Toxin Complexed with its Receptor. Protein Data Bank. 
1999;3.8. 
 
10. Sthilaire PM, Boyd MK, Toone EJ. Interaction of the Shiga-Like Toxin Type-1 B-
Subunit with Its Carbohydrate Receptor. Biochemistry. 1994;33(48):14452-63. 
 
11. Gyles CL. Shiga toxin-producing Escherichia coli: An overview. Journal of Animal 
Science. 2007;85:E45-E62. 
 
12. Strockbine NA, Jackson MP, Sung LM, Holmes RK, Obrien AD. Cloning and 
Sequencing of The Genes For Shiga Toxin From Shigella-Dysenteriae Type-1. 
Journal of Bacteriology. 1988;170(3):1116-22. 
47 
 
 
13. Degrandis S, Ginsberg J, Toone M, Climie S, Friesen J, Brunton J. Nucleotide-
Sequence and Promoter Mapping of the Escherichia-coli Shiga-Like Toxin Operon 
of Bacteriophage-H-19B. Journal of Bacteriology. 1987;169(9):4313-9. 
 
14. Jackson MP, Neill RJ, Obrien AD, Holmes RK, Newland JW. Nucleotide-
Sequence Analysis and Comparison of the Structural Genes for Shiga-Like Toxin-
I and Shiga-Like Toxin-II Encoded by Bacteriophages from Escherichia-Coli 933. 
Fems Microbiology Letters. 1987;44(1):109-14. 
 
15. Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 
Shiga toxin - Producing Escherichia coli. Clinical Infectious Diseases. 
2006;43(12):1587-95. 
 
16. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, et al. Food-related 
illness and death in the United States. Emerging Infectious Diseases. 
1999;5(5):607-25. 
 
17. Brooks JT, Sowers EG, Wells JG, Greene KD, Griffin PM, Hoekstra RM, et al. 
Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 
1983-2002. Journal of Infectious Diseases. 2005;192(8):1422-9. 
 
18. Frenzen PD, Drake A, Angulo FJ, Emerging Infections P. Economic cost of illness 
due to Escherichia coli O157 infections in the United States. Journal of Food 
Protection. 2005;68(12):2623-30. 
 
19. Caprioli A, Morabito S, Brugere H, Oswald E. Enterohaemorrhagic Escherichia 
coli: emerging issues on virulence and modes of transmission. Veterinary Research. 
2005;36(3):289-311. 
 
20. Zhao T, Doyle MP, Shere J, Garber L. Prevalence of Enterohemorrhagic 
Escherichia-coli O157-H7 in a Survey of Dairy Herds. Applied and Environmental 
Microbiology. 1995;61(4):1290-3. 
 
21. Barkocy-Gallagher GA, Arthur TM, Rivera-Betancourt M, Nou XW, Shackelford 
SD, Wheeler TL, et al. Seasonal prevalence of Shiga toxin-producing Escherichia 
coli, including O157 : H7 and non-O157 serotypes, and Salmonella in commercial 
beef processing plants. Journal of Food Protection. 2003;66(11):1978-86. 
 
22. Verweyen HM, Karch H, Brandis M, Zimmerhackl LB. Enterohemorrhagic 
Escherichia coli infections: following transmission routes. Pediatric Nephrology. 
2000;14(1):73-83. 
 
48 
 
23. Mead PS, Finelli L, LambertFair MA, Champ D, Townes J, Hutwagner L, et al. 
Risk factors for sporadic infection with Escherichia coli O157:H7. Archives of 
Internal Medicine. 1997;157(2):204-8. 
 
24. D'Souza JA, Wang L, Reeves P. Sequence of the Escherichia coli O26O antigen 
gene cluster and identification of O26 specific genes. Gene. 2002;297(1-2):123-7. 
 
25. Erridge C, Bennett-Guerrero E, Poxton IR. Structure and function of 
lipopolysaccharides. Microbes and Infection. 2002;4(8):837-51. 
 
26. Norman KN, Strockbine NA, Bono JL. Association of Nucleotide Polymorphisms 
within the O-Antigen Gene Cluster of Escherichia coli O26, O45, O103, O111, 
O121, and O145 with Serogroups and Genetic Subtypes. Applied and 
Environmental Microbiology. 2012;78(18):6689-703. 
 
27. Paton J, Paton A. Methods for detection of STEC in humans. E. coli.2003 (73) 9-
26. 
 
28. De Boer E, Heuvelink AE. Methods for the detection and isolation of Shiga toxin-
producing Escherichia coli. Journal of Applied Microbiology. 2000;88:133S-43S. 
 
29. Deshpande A, White PS. Multiplexed nucleic acid-based assays for molecular 
diagnostics of human disease. Expert Review of Molecular Diagnostics. 
2012;12(6):645-59. 
 
30. Paton AW, Paton JC. Direct detection and characterization of Shiga toxigenic 
Escherichia coli by multiplex PCR for stx(1), stx(2), eae, ehxA, and saa. Journal of 
Clinical Microbiology. 2002;40(1):271-4. 
 
31. Mark JA, Green LD, Deshpande A, White PS, editors. System integration and 
development for biological warfare agent surveillance - art. no. 65401D. 
Conference on Optics and Photonics in Global Homeland Security III; 2007 Apr 
10-12; Orlando, FL2007. 
 
32.  Klein D. Quantification using real-time PCR technology: applications and 
limitations. Trends in Molecular Medicine. 2002;8(6):257-60. 
 
33. Sharma VK, Dean-Nystrom EA. Detection of enterohemorrhagic Escherichia coli 
O157 : H7 by using a multiplex real-time PCR assay for genes encoding intimin 
and Shiga toxins. Veterinary Microbiology. 2003;93(3):247-60. 
 
34. Guy RA, Tremblay D, Beausoleil L, Harel J, Champagne MJ. Quantification of E. 
coli O157 and STEC in feces of farm animals using direct multiplex real time PCR 
49 
 
(qPCR) and a modified most probable number assay comprised of 
immunomagnetic bead separation and qPCR detection. Journal of Microbiological 
Methods. 2014;99:44-53. 
 
35. Biassoni R, Raso A. Quantitative Real-Time PCR Methods and Protocols Preface. 
Quantitative Real-Time Pcr: Methods and Protocols. 2014;1160:V-V. 
 
36. Deshpande A, Gans J, Graves SW, Green L, Taylor L, Kim HB, et al. A rapid 
multiplex assay for nucleic acid-based diagnostics. Journal of Microbiological 
Methods. 2010;80(2):155-63. 
 
37. Woods TA, Mendez HM, Graves SW, Deshpande A. Development of 11-plex 
Assay for the Rapid Screening of Samples for Detection of Shiga toxin-producing 
E.coli. [Unpublished] 
 
38. Federal Registar. Shiga toxin-producing Escherichia coli in certain raw beef 
products. 2011;76:58157-58165.  
 
39. Stucki D, Malla B, Hostettler S, Huna T, Feldmann J, Yeboah-Manu D, et al. Two 
New Rapid SNP-Typing Methods for Classifying Mycobacterium tuberculosis 
Complex into the Main Phylogenetic Lineages. Plos One. 2012;7(7). 
 
40. MOLigoDesigner [internet]; Los Alamos National Laboratory; 2008 [cited 2015 
November 1st]. Available from: http://moligodesigner.lanl.gov/help.html  
 
41. Salkind N. Encyclopedia of Research Design. Thousand Oaks. Sage Publications, 
Inc.; 2010.  
 
42. Thierry S, Hamidjaja R, Girault G, Lofstrom C, et al. A multiplex bead-based 
suspension array for interrogation of phylogenetically informative single nucleotide 
polymorphisms for Bacillus anthracis. Journal of Microbiological Methods. 
2013:95(3):357-365. 
 
43. Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, et al. Dual priming 
oligonucleotide system for the multiplex detection of respiratory viruses and SNP 
genotyping of CYP2C19 gene. Nucleic Acids Research. 2007;35(6). 
 
44. Hussein HS. Prevalence and pathogenicity of Shiga toxin-producing Escherichia 
coli in beef cattle and their products. Journal of Animal Science. 2007;85:E63-E72. 
 
45. Sargeant JM, Amezcua MR, Rajic A, Waddell L. Pre-harvest interventions to 
reduce the shedding of E-Coli O157 in the faeces of weaned domestic ruminants: 
A systematic review. Zoonoses and Public Health. 2007;54(6-7):260-77. 
50 
 
 
46. LuminexCorp [internet]. Madison (WI): Equivalent Analytical Performance 
between the New MAGPIX® System and the Luminex® 100/200™ System. 
[White Paper] [cited 2015 November 1st]. Available from: 
https://www.luminexcorp.com/clinical/instruments/magpix/resources/ 
 
47. LuminexCorp [internet]; 2006[cited 2015 November 1st]. Available from: 
https://www.luminexcorp.com/clinical/instruments/magpix/product-details/ 
 
48. BD Biosciences [internet]; 2015 [cited 2015 November 1st]. Available from: 
http://m.bdbiosciences.com/us/reagents/research/antibodies-buffers/second-step-
reagents/avidinstreptavidin/pe-streptavidin/p/554061 
 
49. Longo MC, Berninger MS, Hartley JL. Use of Uracil DNA Glycosylase to Control 
Carry-over Contamination in Polymerase Chain-Reactions. Gene. 1990;93(1):125-
8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Appendix 
Appendix A: Genomic Sequences for non-O157 Genes Selected 
 The reference genome for each gene selected for the non-O157 MOL-PCR assay is 
listed below (Appendix A.1-A.7). The genes selected for each serogroup were used as input 
sequences in the MOLigoDesigner software. As a result, MOLigo pairs were designed 
based on sequences both upstream and downstream from the SNP location. Referenced 
genomes listed in the Norman et al. study were obtained from GenBank. In parenthesis, 
the GenBank reference number is indicated and the location of the gene within the 
reference genome is also listed. 
Appendix A.1: O26:H11 fnl1 gene (GenBank AY763106:6715-7749)  
ATGTTTAAGAATAAAACACTCGTTATCACTGGTGGCACTGGTTCTTTTGGTAATGCCGTACTTAAGCGTT 
TTCTAGATACAGATATTACTGAAATACGAATATTTAGCAGGGATGAAAAAAAACAAGATGATATGCGGAA 
AAAATATAATAACTCAAAATTAAAATTTTATATAGGTGATGTGCGAGACTATAATTCCGTTCTAAATGCA 
ACGCGTGGTGCCGATTTTCTGTATCATGCAGCAGCCCTTAAACAAGTTCCTTCATGTGAATTTCACCCTA 
TGGAGGCGGTTAAGACAAATGTTCTGGGTACGGAAAATGTTCTGGAGGCTGCTATTGCGAATGGGATTAA 
ACGCGTGGTGTGCTTGAGTACCGATAAAGCCGTTTATCCTATCAATGCAATGGGCATATCTAAGGCAATG 
ATGGAAAAAGTTATTGTTGCAAAATCACGTAATCTTGACAGTTCAAAAACAGTTATCTGTGGAACTCGTT 
ATGGAAATGTAATGGCTTCACGTGGATCGGTCATCCCATTATTTGTTGATCTAATCAAAGCTGGTAAACC 
ATTGACCATAACCGATCCCAATATGACTCGTTTCATGATGACGCTTGAGGATGCTGTCGATCTGGTCCTT 
TATGCTTTCGAACATGGAAATAATGGTGACATTTTCGTTCAGAAAGCACCTGCGGCAACAATTCAAACAT 
TAGCCATTGCACTTAAGGAATTGCTAAATGCCCATGAGCATCCAATCAATATTATTGGAACTCGACACGG 
GGAAAAACTTTACGAAGCGTTATTGAGCCGAGAGGAAATGATTGCAGCGGAAGATATGGGTGATTATTAT 
CGTGTTCCACCAGATCTCCGCGATTTGAACTATGGAAAATATGTGGAACATGGTGACCGTCGTATCTCGG 
AAGTGGAAGATTATAATTCTCATAATACTGAGAGATTAGATGTTGAGGGAATGAAAGAATTACTGCTAAA 
ACTTCCTTTTATCCGGGCACTTCGTTCTGGTGAAGATTATGAGTTGGATTCATAA 
Appendix A.2: O26:H11 wzx gene (GenBank AY763106: 3543-4805) 
ATGTTGAAAAAAAAACTTCAAAAAATAAAGGAATATCATTCAGTATTGGAGTTGGCAATAATTCAGGGTG 
CGAATGCCATATTTCCTGTGTTGGTATTCCCATTTTTTCTTATTACCTTAGGGGAAAACATCTTTTCAAG 
TATTGCTGTTGGTGAAGTACTAGCACTATATGTGCTTATATTTTCGCTATACAGTTTTGATATTATAAGT 
GTGCAGAAGGTAATTTCAAGTGTGACAAAAGATGAAATATTTAAAGTTTACATTCTGACACTAATCTGTA 
GGTTGTGTTTATTTGTTATTTCAGGAATATGTCTTTTATTTATAACGTATTTAATTAATAAAACATTAAG 
TGTATACTTGGGATTGTTTTTATTGTACCCAGTAGGGATGATATTGCAATCTAATTATTTTTTTCAGGCT 
ACGAATAACAATAGGCCATTGGCTGTTTTTGTACTAATTGCTCGTGGTATGTCATTATGTCTTATTTATT 
TTTATAATGGACCAGCAGGCTATTTAACAAGTTATTATTATGTCATTTGTGTGTCTGGTTCGTATTTTTT 
ATCTGGCGTGCTATCGCTTATATATATATATTATCAAAATAAGACTAATAAAGCTAAAATTCAATGGGCG 
GAAATTTTAGAATATATATGCACAGGTTATCATCTGTTTATTGCTAATATATTTGTTATTCTATACAGAA 
ATAGTAATATTATTATTCTTGGCACTCTTGCTTCGCCTGTTGCAACGTCTCTGTACGCGACGGCAGAGAA 
AATTATTAAATGTATTCAGTCTATAGCAACCCCGTTAAATCAATACTATTTCACGAGGTTGATAAAGCAA 
CATGAATTGAAATTAGAACCATACAAAGTTGGAGAATATAAAAGCCTGCTATATGCAAGCACAAATATTC 
AGCTAAAGTTCATGGTTTTCATTGTCCTGAGTTTAGGGGGGGTGGGTACTATATTGGGATATAAGGTTCA 
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AAGTATCGCTGAAATTAGAAGCGCGTTCATCCCTTTATCAATAATGTCTTTTGCAATATTTATGGGGATA 
TACAATTTTATGTTTGGTTCGGTTGGATTGTCCATAAGAGGGTATAAAAAAGAATTTTCTTATATAGTGG 
CCATTACGGGTGTTTCAACTATTATTTTATCATTATGCCTGAGTTATTTCTTTGCTGAAATAGGCGCTGC 
AATTGCTTATGTATTTGCTGAGTTTATCTTACTTATTCTCATACTTAGAATTTATAAAGTGAAACGATTA 
TAA 
Appendix A.3 O45 wbhQ gene (GenBank AY771223: 2196-3230) 
ATGTTATATCTGGGCATTGTCGTTTTTGCATTCTTTATATCATGCGCGTTGACTTGGGGTTTAAGGTTAT 
ATGCCATCAAGAATAATGTAATTGATCAACCAAACCAAAGAAGTTCTCACAGTGTTCCTACGCCTCGTGG 
GGGAGGGGTGGCTATTGTATTAACATTGTTGGCTTCATTAATATGGCTGGTCCTTACAAATCATATAACT 
CAGGCAACATTTTTAGGTTTCTTCGTGACTGGCTTATTGATTGCGGTTATTGGTTTCCTCGACGATCATG 
GCCATATCGCTGCACGCTGGCGCTTGTTAATGCATTTCATCGCTGCAGCTATAGGGCTTTTTTATCTAGG 
ATCTTTCCCAAGCATTAATATGTTTGGCTACGATGTTTCTTTGTCATGGTTTGGAATGATCCTCGGTAGT 
ATCTATCTTGTATGGATGTTGAATTTATATAACTTTATGGATGGTATTAATGGTCTTGCAAGTGCGCAAG 
CTATTACCTTTTCGCTTTGTAGTATCTTGATAATAACTATCAATAACTACTCTGATTCATCTGATGCAAT 
GACTATGCTTGCATTAGCACTCGCTGGATCGGTCGCGGGATTCATCGTGTGGAACTTCCCTGTGGCAAGG 
ATCTTCATGGGCGATGCTGGAAGCGGTTTTCTGGGTATCACCATTGGGCTGATGATCCTTTATTTTGCAA 
AGCTAGACTCACGTGTTCTGATCGCAGAACTCTGTCTGCTGGGTGTTTTCATTGTTGATGCAACTACTAC 
CTTACTGAGAAGATTACTGGCGGGTAAGAAAGTCTATGAAGCACATGCAAGTCATTGTTACCAAATTCTT 
GCCCGTAAATATAAGAGCCATGTTCCTGTTACTATGGCGGCTATAGCTATTAACTTCATGTGGCTGCTCC 
CTATTGCTTACTTAATCATCTCTGCAAAAATTGATGGAATTGTAGGCATTACCATCGCTTGGTTACCATT 
GATGATTCTTGCATTCAGATGTGGTGCTGGAGTTAAAGATAAAGAGAGGGCATAA 
Appendix A.4 O103 wbtD gene (GenBank AY532664: 5353-6339) 
ATGATAATATCTTCAGATAACCTAAGTGTTATTATCCCAGTTTATAATGAAGAGAAGAATGTTATTAATA 
TTCTTCAATCTCTTGAATGCCAGTCTTTAACGGGATTTAATGTTATTGTCATTGATGATGGTTCAAAAGA 
TATGACTGCTTCTCTTGTAAAAGAATATAAACCATCATCATATAGTTTAAGCTTAATACAACAAAGTAAT 
ATGGGGGCTGCTCGGGCAAGGGAGAATGCCATCAATTTTACTCATAGTGAGTATATTGCATTTATAGATA 
GTGATGACTCTTTAAGTTCAGATGCTCTTGAAAAAGCATTAGCTCCGATGCTGGATAATAAAGATATCGA 
CATCTCACTATTTGAACTGGTACATATTAAAAACTTAAATCATGATACTAATAACATATTTGTACCTTAT 
TCTACAACCAAATTAATATGTGGAGAAGAGGCTTTTGCTAATTGTATTTCATATTGGGGATTGCATGGGT 
TTGGTATCTACAAAAGAAAATTGATTCAAAAATCCTATGGTATTTATTATAAATATAATAAAAACAAAGA 
AAATTATATAAATAATGATGAGGTTATTTCAAGAATCAGTTTTGGATTATCTAAAAATATCTATTTATCA 
TCTGGAAGATATTTCTTTGTACAGAACATGGATTCAACAACAAGAAGAATAAATGAAAGTTATTATAAAG 
TTATAAATAATGCTGTTTATTTAAGAGAGTATATAGATGAAGAAATAAAATATAATGATTTTGATTGTCT 
AGGTGAAGCTAATAAACTCCTTGTAAGTACTATATGGGGAGTGTTTGTTCGTTATCAAAAATGGAAGAAA 
AAATTCAGTGATGAAACAAACGGTAAATGGCGCGAAGCAATAAAAAAAGGAATGCAATATATAAAAAAAA 
TCAATAACAATAAGAATATTAACCTGCATATTAAATCTAAAATGCAATTATATATAATATCTAAACTTGT 
TAGCTAA 
 
Appendix A.5 O111 wbdK gene (GenBank AF078736: 7441-8607) 
ATGATTACATACCCACTTGCTAGTAATACTTGGGATGAATATGAGTATGCAGCAATACAGTCAGTAATTG 
ACTCAAAAATGTTTACCATGGGTAAAAAGGTTGAGTTATATGAGAAAAATTTTGCTGATTTGTTTGGTAG 
CAAATATGCCGTAATGGTTAGCTCTGGTTCTACAGCTAATCTGTTAATGATTGCTGCCCTTTTCTTCACT 
AATAAACCAAAACTTAAAAGAGGTGATGAAATAATAGTACCTGCAGTGTCATGGTCTACGACATATTACC 
CTCTGCAACAGTATGGCTTAAAGGTGAAGTTTGTCGATATCAATAAAGAAACTTTAAATATTGATATCGA 
TAGTTTGAAAAATGCTATTTCAGATAAAACAAAAGCAATATTGACAGTAAATTTATTAGGTAATCCTAAT 
GATTTTGCAAAAATAAATGAGATAATAAATAATAGGGATATTATCTTACTAGAAGATAACTGTGAGTCGA 
TGGGCGCGGTCTTTCAAAATAAGCAGGCAGGCACATTCGGAGTTATGGGTACCTTTAGTTCTTTTTACTC 
TCATCATATAGCTACAATGGAAGGGGGCTGCGTAGTTACTGATGATGAAGAGCTGTATCATGTATTGTTG 
TGCCTTCGAGCTCATGGTTGGACAAGAAATTTACCAAAAGAGAATATGGTTACAGGCACTAAGAGTGATG 
ATATTTTCGAAGAGTCGTTTAAGTTTGTTTTACCAGGATACAATGTTCGCCCACTTGAAATGAGTGGTGC 
TATTGGGATAGAGCAACTTAAAAAGTTACCAGGTTTTATATCCACCAGACGTTCCAATGCACAATATTTT 
GTAGATAAATTTAAAGATCATCCATTCCTTGATATACAAAAAGAAGTTGGTGAAAGTAGCTGGTTTGGTT 
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TTTCCTTCGTTATAAAGGAGGGAGCTGCTATTGAGAGGAAGAGTTTAGTAAATAATCTGATCTCAGCAGG 
CATTGAATGCCGACCAATTGTTACTGGGAATTTTCTCAAAAATGAACGTGTTTTGAGTTATTTTGATTAC 
TCTGTACATGATACGGTAGCAAATGCCGAATATATAGATAAGAATGGTTTTTTTGTCGGAAACCACCAGA 
TACCTTTGTTTAATGAAATAGATTATCTACGAAAAGTATTAAAATAA 
Appendix A.6 O121 vioA gene (GenBank AY208937: 4455-5558) 
ATGGAAAAGCCAATCTTTGTAACGCAACCTAATTTACCACCGCTAGAGGAGTTTATACCATATCTGGAAA 
TCATTTGGCAGAATAAGCAATTTACAAATAATGGTCCAATGCATCAAAAATTAGAAAAAAAATTATGCGA 
GTTTCTTGGTGTTGAATACATTAGTCTATTTAATAATGGGACTATTGCGCTTATAACCGCAGTACAGGCT 
TTGGGTGTTAAAGGCGAAGTAATTACCACACCATATTCCTTTGTAGCAACTGCACACTCCTTGGTCTTAA 
ATGGGCTTAAACCTGTTTTTGTCGATATTGATTCCAAAACCTTAAATATCGATCCGAGAAGAATTGAAGA 
GGCGATTACCCCTGAAACGCAGGCAATAATGCCGGTGCACTGCTATGGGAATCCTTGCGATACACAAGCT 
ATTGCTGATATTGCGCAAAAATATAATTTAAAGGTCATTTATGATGCTGCGCATGCCTTTGGCGTTGAAG 
ATGATGATGGAAGTGTTCTTCGCCATGGAGATCTAAGTGTCTTAAGTTTCCATGCAACTAAAGTGTTCAG 
CACTTTTGAAGGCGGAGCTATTGTGTGTAATAGTAAAGAAATGAAAGAAAAAATTGATAGACTAAAAAAC 
TTTGGTTATATCGATGAAACTAACATCAATATCATTGGCTCTAATGGAAAAATGAGCGAAGTTAATGCTG 
CTTTCGGCTTGCTACAATTAGAACATATGGATACTTTTCTACGTGGTCGAATGAATGCTGACATGTTTTA 
TCGGCAGAAACTTAAAGATATCACTGGTATAAGCATAGTAATTCCCAGCGGCCAGAAAATATCGAATTTT 
TCATATTTCCCTATATTGGTTGAATCTGATTTTCCGTTATCTCGTGATGAACTATTTAATTATCTGAAGA 
ACCAGAATATTTTTGCAAGACGTTATTTTTATCCTGTTATACCAGATTTTCAAGCGTATTTGAATGTAGG 
TGAAGTCTGTGATGTCAAGAATGCCCGTGAAATAGCCTCGAAAGTGCTTTGCCTACCGATGCATGCAGAA 
TTGAGCTCTGATATCTTAGAATATATTGTAAGTACGATTAGGGAGATTAAATGA 
Appendix A.7 O145 wzy gene (GenBank AY647260: 5615-6802) 
GTGAATATAAAGAAAGATAAGTTTATAAATGGAGTGATTTTTTTTTGGTTAATTATTTCTTCGTTATATT 
ACTTAAATGCTATTTTTTCTGGTGTTGACACATTAAAATATAATGAAGATTTAACGCAAAAAATTATAAA 
ATATATAGTTTGCTTAGTTATAAGTCTAAGTATCTTATTTATTTACAAGAAATTTAATTATTTTTTTGTA 
TTGTTTTTTTTCTTGTTCCTGTCTGTTGCTTCAGCCCTTTTCAGTGGTGCGGTAACAATTTACGCAACAA 
CAATGTTGATTATTGCAACTATGATCAGCTTTTGCCTGATTATTCCTCTATTTTCTTATAATATGGTGAA 
AGTTAATAGAGTTCTTTTATGGACAGGAGTTATTGTAGGCACGATTTCTGTATTAGAATTAACGGTATTT 
TATAATTATATGGTTTCATATTGGGCTGCCACTGATGGGATTAGGTCAATATCTTCTCTTCTGAATCCTA 
CGAATAGTGGTGCTTATTCAGCGATTATTATTTTAATCGCCTTGGTGACAAATATAAAAAGTCTTTTTAA 
AAGAGCTTTATTTCTTATAATGCCGATGATAACGTTAATTAGCAGTGGTTCGCGCACAGCATGGTTATCA 
CTTGGTATGACACTTTTATTAACAGTAGTATTGAGAGACAGTGCCAGCATTCGCTTGCGAAAAAAAATAT 
TTACTCTTGCAAGCATTGGCACTGTTTGCGGTGCATTGTACGCCATATTTTATATGGGCAGTATCTCTGG 
TATTGAATCACAATATCGAGGTCTTAATACGTATACTGCATCAATTCGAGTTGAAAACTTTCTGACATAT 
TTAAATTTAGTTGATCTGAATATGTTGCTACCTGATTTTTTAGATAAAAATATAAATCTCATTTCAGATA 
ACTTTTATCTCGTAATGTTTAATTATGCCGGTCTAATCGGCTTTTTTATTGTTTTATTAATTTTATTGCT 
GCTTATCTTCTGGAACATACAATTTAAAATATTTAATGAGTTAATGGCTGAAGATATAGCCATTTGGAGA 
GTTGTTTTTATTTATTTCCTAATATCCGGGCTTTCAAATTCATTTATAAATTCTTTTCCTGTAAATCAAT 
TGTTCTTTATCTCATGCGGATATTATATATATAAATATAAATTAGTTAAAAGCTCTATAGGAAGATAA 
 
Appendix B: Critical Values for Wilcoxon Rank Sum  
 The Wilcoxon Rank Sum test was used as a statistical analysis tool for the MOL-
PCR assay. The identification of each serogroup was determined by using either the 
approximate or the exact Wilcoxon Rank Sum Test. Listed below are the critical values for 
the exact Wilcoxon Rank Sum test based on a 0.05 one-tailed Z-test. The table lists the 
critical values for each n value. The critical value most often used in this assay was 27. The 
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N1 value corresponded to the number of sample replicates (3) and the N2 value 
corresponded to the number of no template control samples (8). Therefore, the chart was 
used to predict the critical value based on the number of sample replicates and the number 
of blanks. The critical value was compared against the sum of the ranks for the sample 
group to determine if the sample was positive or negative for a particular group (Chapter 
3, Section 6). 
 
 
 
Appendix C: Complementary Synthetic DNA Sequences for Assay Development 
  Appendix C contains the sequences for the synthetic complementary target 
sequences developed for the training panel. The training panel consists of synthetic 
oligonucleotides for both the STEC and non-STEC O26 genes (fnl1 and wzx). The 
training panel aided in the optimization of both the ligation and the PCR conditions. The 
synthetic target sequences were developed from the reference genomic sequences listed 
in Appendix A.1 and A.2.  
Serogroup SNP Sequence (5’-3’) 
O26 S-wzx T  TCA TTG TCC TGA GTT TAG GGG GGG GGG GTA CTA TAT TGG GAT ATA AGG TTC AAA GT 
 
O26 NS-
wzx 
G TCA TTG TCC TGA GTT TAG GGG GGG TGG GTA CTA TAT TGG GAT ATA AGG TTC AAA GT 
 
O26 S-fnl1 G ATG CCG TAC TTA AGC GTT TTC TAG ATA CAG ATA TTA CTG AAA TAC GAA TAT TTA GCA 
GGG ATG AAA A 
 
O26 NS-
fnl1 
A ATG CCG TAC TTA AGC GTT TTC TAG ATA CAG ATA TTG CTG AAA TAC GAA TAT TTA GCA 
GGG ATG AAA A 
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Appendix D: Strain identification and virulence profiles for DNA panel 
 In Appendix D.1 and D.2 are the strains that were included in the STEC DNA 
panel. Each panel was tested against the computationally designed MOLigo pairs. Table 
4.2-4.6 list the results of the MOL-PCR assays evaluated against each DNA panel. 
Described below are the strain identification numbers, serotypes, and virulence genes 
associated with each strain.  
Appendix D.1: non-O157 Strains tested in Singleplex Assay 
 The strains listed in this table were obtained from ATCC. The strain is listed by 
ATCC identification number and serotype. The virulence profile for each strain is listed 
below. The ATCC samples were used for optimization of the STEC non-O157 assay. 
ATCC samples consist of purified genomic DNA and were instrumental to determine 
MOLigo pair performance. 
Strain ID Serotype stx1 stx2 eae 
BAA-2196 O26:H11 Positive Positive Positive 
BAA-2193 O45:H2 Positive Negative Positive 
BAA-2215 O103:H11 Positive Negative Positive 
BAA-2440 O111 Positive Positive Positive 
BAA-2219 O121:H19 Negative Positive Positive 
BAA-2192 O145:NM Positive Positive Positive 
 
Appendix D.2: non-O157 Strains tested in 8-plex STEC and non-STEC Assays 
   The strains listed in this table were obtained from Kansas State University (KSU). 
Each strain is identified by serotype and strain ID number. The strains are identified based 
on their virulence profiles (stx1, stx2, and eae). The strains were obtained from clinical 
isolates associated with samples obtained from human stool. The strains were used to 
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optimize the STEC non-O157 assay and have also been used to evaluate the SNP 
specificity for the non-STEC assay.  
Strain ID Serotype stx1 stx2 eae 
H30 O26:H11 Positive Negative Positive 
CDC 96-3285 O45:H2 Positive Negative Positive 
CDC 90-3128 O103:H2 Positive Negative Positive 
JB1-95 O111 Positive Positive Positive 
CDC 97-3068 O121:H19 Negative Positive Positive 
83-75 O145:NM Negative Positive Positive 
 
Appendix E: Original Design for MOL-PCR Assay 
 The table listed in this Appendix includes the original design of each MOLigo pair 
for both the STEC and non-STEC assays. The singleplex assay and the initial evaluation 
of the 8-plex assay were performed with the MOLigo pairs listed in this table. The MOLigo 
pairs had to be redesigned when the assay was evaluated on the Luminex MagPix®. The 
beads originally selected for O26 non-STEC fnl1, O26 STEC and non-STEC wzx, O103 
STEC wbtD, O111 STEC wbdK, and O145 wzy, were not available on the Luminex 
MagPix®. Each MOLigo pair listed above was redesigned with beads that were available 
on the MagPix®. 
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Serogroup xTAG SNP MOLigo Sequence (5’-3’) 
 
O26 S-
fnl1 
 
A042 
 
A 
M1 /5Phos/AAT ATC TGT ATC TAG AAA ACG CTT AAG TAC 
TCT CAC TTC TTA CTA CCG CG 
 
M2 ACT CGT AGG GAA TAA ACC GTA TTT GTT ATG ATA 
AAT GTG TAG TGA TCC CTG CTA AAT ATT CGT ATT 
TCA GT 
 
 
O26 NS-
fnl1 
 
B098 
 
G 
M1 /5Phos/AAT ATC TGT ATC TAG AAA ACG CTT AAG TAC 
TCT CAC TTC TTA CTA CCG CG 
 
M2 ACT CGT AGG GAA TAA ACC GTA AAT GTG TGT TTA 
GTA GTT GTA AAC CCT GCT AAA TAT TCG TAT TTC 
AGC 
 
 
O26 S-
wzx 
 
B082 
 
G 
M1 /5Phos/CCC CCC CTA AAC TCA GGA CTC TCA CTT CTT 
ACT ACC GCG 
 
M2 ACT CGT AGG GAA TAA ACC GTA TTT GTA TAA AGT 
GAA GAA GAG AAG AAC CTT ATA TCC CAA TAT AGT 
ACC CC 
 
 
O26 NS-
wzx 
 
B009 
 
T 
M1 /5Phos/CCC CCC CTA AAC TCA GGA CTC TCA CTT CTT 
ACT ACC GCG 
 
M2 ACT CGT AGG GAA TAA ACC GTG AAT TGT ATA AAG 
TAT TAG ATG TGG AAC CTT ATA TCC CAA TAT AGT 
ACC CA 
 
 
O45 S-
wbhW 
 
A057 
 
A 
M1 /5Phos/TCT GAT ATG AGT CGA ACA TAA TGT TTT TAC 
TCT CAC TTC TTA CTA CCG CG 
M2 ACT CGT AGG GAA TAA ACC GTA GAG TAT TAG TAG 
TTA TTG TAA GTA GTT AAA TAG ATT AGA TAT CTT 
TAT TTA AAC AAC ATC TTA 
 
O45 NS-
wbhW 
 
A051 
 
C 
M1 /5Phos/TCT GAT ATG AGT CGA ACA TAA TGT TTT TAC 
TCT CAC TTC TTA CTA CCG CG 
M2 ACT CGT AGG GAA TAA ACC GTG ATA AGA AAG TGA 
AAT GTA AAT TGG TTA AAT AGA TTA GAT ATC TTT 
ATT TAA ACA ACA TCT TC 
 
O103 S-
wbtD 
 
B096 
 
T 
M1 /5Phos/CAG GTT AAT ATT CTT ATT GTT ATT GAT TTT 
TTT TAT ATA TTG TCT CAC TTC TTA CTA CCG CG 
M2 ACT CGT AGG GAA TAA ACC GTT ATG TGT ATG AAG 
ATT ATA GTT AGA CAA GTT TAG ATA TTA TAT ATA 
ATT GCA TTT TAG ATT TAA TAT A 
 
O103 NS-
wbtD 
 
A073 
 
C 
M1 /5Phos/CAG GTT AAT ATT CTT ATT GTT ATT GAT TTT 
TTT TAT ATA TTG TCT CAC TTC TTA CTA CCG CG 
M2 ACT CGT AGG GAA TAA ACC GTG TTG AGA ATT AGA 
ATT TGA TAA AGC AAG TTT AGA TAT TAT ATA TAA 
TTG CAT TTT AGA TTT AAT ATG 
  
B086 
 
T 
M1 /5Phos/CCT GTA ACC ATA TTC TCT TTT GGT AAA TTT 
CTC ACT TCT TAC TAC CGC G 
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Appendix E: Evaluation of Samples on Luminex MagPix® 
 The MOL-PCR assay was evaluated on the Luminex MagPix® instrument. The 
MagPix instrument is identified as a compact fluorescence-based detection system that uses 
light-emitting diodes (LEDs) and a CCD camera to detect 50 different analytes.46 The 
MagPix® is not considered a flow cytometer, but is identified as a fluorescent imager.46 
The MagPix system® is used with xMAP magnetic microspheres that are color-coded and 
O111 S-
wbdK 
M2 ACT CGT AGG GAA TAA ACC GTG TGT GAT TAG TAA 
TGA AGT ATT TAA CTC TTC GAA AAT ATC ATC ACT 
CTT AGT A 
 
O111 NS-
wbdK 
 
A026 
 
C 
M1 /5Phos/CCT GTA ACC ATA TTC TCT TTT GGT AAA TTT 
CTC ACT TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTT TTG ATT TAA GAG 
TGT TGA ATG TAC TCT TCG AAA ATA TCA TCA CTC 
TTA GTG 
 
O121 S-
vioA 
 
A063 
 
T 
M1 /5Phos/ATC AAT ATC GAC AAA AAC AGG TTT AAG 
CTC TCA CTT CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTT TTG TTG TTA AGT 
ATG TGA TTT AGT CGG ATC GAT ATT TAA GGT TTT 
GGA 
 
O121 NS-
vioA 
 
A053 
 
C 
M1 /5Phos/ATC AAT ATC GAC AAA AAC AGG TTT AAG 
CTC TCA CTT CTT ACT ACC GCG 
M2 ACT CGT AGG GAA TAA ACC GTG TTT GTG TTT GTA 
TAA GTT GTT AAT CGG ATC GAT ATT TAA GGT TTT 
GGG 
 
O145 S-
wzy 
 
B089 
 
C 
M1 /5Phos/CAC TCC ATT TAT AAA CTT ATC TTT CTT TAT 
ATT CAT CTC ACT TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTT AGA TAA TGT GAA 
GTA ATA AGT GAA GTA ATA TAA CGA AGA AAT AAT 
TAA CCA AAA AAA AAG 
 
O145 NS-
wzy 
 
A055 
 
A 
M1 /5Phos/CAC TCC ATT TAT AAA CTT ATC TTT CTT TAT 
ATT CAT CTC ACT TCT TAC TAC CGC G 
M2 ACT CGT AGG GAA TAA ACC GTG AAG ATA TTG AAA 
GAA TTT GAT GTA GTA ATA TAA CGA AGA AAT AAT 
TAA CCA AAA AAA AAT 
 
Ligation 
Control 
 
 
A056 
 M1 CTT TGG GGA TTA GCT CCG CTC TCA CTT CTT ACT 
ACC GCG 
 
M2 ACT CGT AGG GAA TAA ACC GTA ATT AGA AGT AAG 
TAG AGT TTA AGT GCA ATC CGA ACT GAG ATG GA 
 
Forward 
Primer 
    
 
/5Alex488N/CGC GGT AGT AAG AAG TGA GA 
 
 
Reverse 
Primer 
   ACT CGT AGG GAA TAA ACC GT 
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allow for multiple analytes to be evaluated in a single sample.46 The magnetic microspheres 
used in this assay were xTAG® microspheres that were coupled to a 24-base 
oligonucleotide sequence.46  
The components of the MagPix® consists of a fluidics system and an optics 
module. The fluidics system has the following components; syringe pump, sample probe 
and a sample valve.46 The optics module for this instrument consist of four main 
components: 1) sample chamber, 2) magnet, 3) Light emitting diodes (LEDs), and 4) CCD 
camera.46 The samples are analyzed by a sample probe that draws the sample from the 96-
well plate into the instrument.47 The beads are transferred to the sample chamber. The 
magnetic plate is position at the back of the sample chamber where the microsphere are 
arranged in a monolayer along the magnetic plate.47 Red LEDs illuminate the sample 
chamber and the CCD camera images the fluorescent microspheres based on the color-
coded beads.47 Green LEDs illuminate the sample chamber to capture whether the sample 
analyte is present.47 The software then processes the images and determines concentrations 
of the analytes.47 The magnet is moved away from the sample chamber allowing for the 
sample to be removed from the sample chamber.47 The reporter channel excitation (LED 
excitation) is 511 nm. SAPE was used in this research and has an excitation of 496 nm and 
an emission maximum at 578 nm.48 
Appendix F: dUTPS and Uracil DNA- glycosylase Treatment 
 The polymerase chain reaction (PCR) is an essential component for molecular 
diagnostics. Amplification via target amplification or signal amplification generates a 
multitude of PCR products that allows for detection by end point detection, RT-PCR, or 
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by flow cytometry.29, 49 Generating PCR products increases the susceptibility for potential 
problems associated with PCR contamination.49 Contamination can occur as a result of 
cross-contamination between samples, contamination for laboratory environment, and 
carry-over contamination from previous experiments.49 As a result, the three sources of 
contamination could lead to false positive results.49 Often determining the source of 
contamination is time-consuming and can get very expensive.49    
 A method to control carry-over contamination involves the introduction of 
deoxyuridine triphosphate (dUTPs) and uracil DNA glycosylase (UDG) into the ligation 
and PCR reactions.49 UDG is an enzyme that is capable of removing uracil bases from 
DNA by cleaving the N-glycosidic bond located between the base and the sugar-phosphate 
group.49 This results in the production of an apyrimidinic site that prevents DNA 
polymerase from generating a new product.49 The incorporation of dUTPs in the PCR 
reaction replace dTTPs, generating PCR products that contain uracil bases rather than 
thymine.49 UDG treatment is employed prior to beginning the next reaction (during 
ligation), preventing amplification of previous PCR products. UDG is inactivated during 
the DNA denaturation step, preventing the enzyme from degrading the product that is being 
generated in the current experiment.49 Identified below is the location of the bond cleaved 
by UDG.  
 
Deoxyuridine Triphosphate 
(dUTPs) 
N-glycosidic bond cleaved 
by UDG enzyme 
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Appendix G: Standard Operating Procedures for MOL-PCR Assay 
 The MOL-PCR assay chemistry is considered an open system. With the separation 
of the ligation and amplification reactions, the risk of contamination for this assay increases 
substantially. To limit the chances for contamination, a standard operating procedure is 
strictly followed. The laboratory contains three work stations where a unilateral workflow 
is employed. The first workstation (Pre-PCR Workstation) is used for mixing ligation and 
PCR reagents. In this workstation, reagents for ligation and PCR are mixed before template 
DNA is added to the reaction. The second pre-PCR workstation is where template DNA 
and ligation product is added to the reaction. The third PCR station is the post-PCR 
workstation, which is in a separate room on the opposite end of the lab. The addition of 
microspheres are added to the post-PCR product and all wash steps are completed in this 
workstation. The workstations are cleaned with 20% bleach after each use and all pipettes, 
tubes, tube racks, non-DNA solutions undergo UV irradiation for 30 minutes. The 
incorporation of the SOP has greatly reduced contamination issues that were previously 
experienced. Below is the standard operating procedure that is used for the MOL-PCR 
assays. 
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MOL-PCR Standard Operating Procedures 
The entire STEC MOL-PCR assay will be done in three separate areas to prevent any contamination from 
one process into processes further down the line. There will be a Master Mix preparation area where all 
reagents that do not contain DNA other than the MOLigos will be made. There will be a separate area where 
the Template DNA and any positive control DNA will be added before ligation procedure. This area will also 
be where the transfer from ligation product to PCR reaction will take place. There will then be a third area 
where the post-PCR reactions and setup will take place that is in a completely separate laboratory.   
Ligation Master Mix Preparation 
1. Enter the pre-PCR lab space and immediately put on lab coat followed by nitrile gloves. 
2. Open the MM PCR hood and place any tips, racks, Eppendorf tubes, water aliquots needed for the 
day inside and turn on the UV light inside for ~30 minutes, if not already done. 
3. After the consumables have properly been irradiated by UV light then proceed on to the next steps. 
4. Get the ligation freezer box from the freezer in the other room and bring into pre-PCR lab. Wipe the 
outside down with 10% bleach and place it inside of the hood. 
5. Remove gloves and replace with new, clean nitrile gloves. 
6. Remove the SSDNA, ligation buffer, and MOLigo mix and centrifuge them to help them thaw 
quicker. This should be done inside of the hood using only items that have been UV treated. 
7. Once these items have thawed make sure to mix them well before dispensing volumes. 
8. Dispense water into 3 tubes: 1 for MOLigo dilution, 1 for SSDNA dilution, and 1 for Master Mix. 
9. Dilute the MOLigo Detection Mix for the STEC MOLigos (M1 and M2 are each at 25uM) to 100nM 
by adding 496uL of water and 2uL of each m1 and m2 STEC MOLigos. Make working 
concentration by diluting 100nM detection mix to 20nM (40uL MD+160uL H2O). 
10. Dilute Salmon Sperm DNA in water to 12uL DNA to 68uL water. 1.5mg/ml SSDNA. Remove 
gloves and replace with new nitrile gloves 
11. Use the chart below to add the correct volumes of components to the Master Mix tube. 
Component 
Volume per 
reaction (uL) 
Total # 
reactions 
 Master 
Mix 
Volume 
(uL) 
HPLC H2O 11.2 0 0 
1.5mg/mL Salmons Sperm DNA 2 0 0 
10X Pfu Buffer (1X final) 2 0 0 
Non-STEC MOLigo(s) (20nM in.) (2nM fin.)(each)  2 0 0 
Uracil-DNA Glycosylase 5u/uL (1U/20uL) 0.5 0 0 
Ampligase (5U/uL) (1U/20uL reaction) 0.5 0 0 
Master Mix Volume 18   0 
Template DNA 2   0 
Total Volume 20   0 
12. Re-cap PCR Mix tube, briefly vortex, spin down and place back in workstation. 
13. Take out a new 96 well plate from sealed bag.  
14. Dispense equal volume of MM solution into 1 strip of 8-tube strip, for easy dispensing into PCR 
plate.  
15. Use the multichannel pipette to dispense 18uL of MM from strip tubes into 96 well plate.  
16. Inspect PCR plate to check that all appropriate wells have been filled and volumes appear consistent. 
Seal PCR plate. 
17. Remove sealed plate from PCR hood and set on bench next to hood.  
18. Seal the waste container bag and remove from hood, dispose of bag in large container.  
19. Spray inside area of PCR hood with 10-20% bleach solution and wipe down thoroughly.  
20. Follow bleach with water and dry towel. 
21. Refill the tips, racks and other used items for next assay and UV irradiate for 30 minutes. 
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22. Return the freezer box to the -20 C freezer.  
23. Remove gloves and replace with new nitrile gloves. 
 
Ligation DNA Addition Station     
24. Inspect the DNA addition PCR hood to make sure all the consumables needed are present. 
25. Any items that are not present and have not been UV cleaned will need to be 20% bleach cleaned 
before being put into the PCR hood.  
26. Move the MM containing PCR plate into the hood.  
27. Remove seal from PCR plate, dispose and change gloves.  
28. Using tips from a new box begin adding test reagents to plate. 
29. To the first 8 wells of the plate add the negative control, then remove and replace gloves. 
30. Add the DNA to be tested to each of their corresponding wells in triplicate, then remove and replace 
gloves.  
31. Add the positive controls to the last 8 wells of the plate, then remove and replace  
gloves.  
Plate Layout 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
32. Remove plate from the PCR hood and place in thermo cycler and run the ligation protocol.  
 Ligation Conditions: 
 1. 37°C      30 minutes                (UDG Treatment) 
 2. 95°C        3 minutes 
 3. 95°C      25 seconds 
 4. 58°C        2 minutes 
 5. Repeat steps 3-4 x30 times 
 6.  95°C      30 minutes               (UDG Inactivation) 
 6. Hold 4°C 
33. Return to your workstation, dispose of all waste, change gloves, and bleach entire workstation. 
34. Follow bleach with water and dry towel, then UV irradiate workstation. 
35. Return to entry and remove PPE (gloves, then glasses and coat). 
PCR Master Mix Preparation     
1. Enter the pre-PCR lab space and immediately put on lab coat followed by nitrile gloves.  
2. Open the MM PCR hood and place any tips, racks, Eppendorf tubes, water aliquots needed for the 
day inside and turn on the UV light inside for ~30 minutes, if not already done.  
3. After the consumables have properly been irradiated by UV light then proceed on to the next steps.  
4. Get the benchtop freezer box from the freezer in the other room and bring into pre-PCR lab. Wipe 
the outside down with 10% bleach and place it inside of the hood. 
5. Remove gloves and replace with new, clean nitrile gloves.  
6. Remove the 10X PCR Buffer, 25mM MgCl2, dUTP mix, Forward and Reverse Primer. Place 10X 
buffer and MgCl2 reagents into the centrifuge to reduce defrosting time. Centrifugation of reagents 
will be done inside the hood using the UV treated centrifuge. 
7. After the reagents have thawed, make sure to mix them well before dispensing volumes 
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8. Use the chart below to add the correct volumes of components to the Master Mix tube 
Component Volume per 
Total # 
reactions 
Master Mix 
Volume 
HPLC Water 10.05 0 0 
10X PCR Buffer (1X final) 2 0 0 
25mM MgCl2 (4mM final) 3.2 0 0 
dUTP Mix (200uM(A,C,G), 400uM(U) 
final) 2 0 0 
Forward Primer (0.5uM final) 0.5 0 0 
Reverse Primer (0.1uM final) 0.1 0 0 
Amplitaq Gold (0.05U/uL final) 0.15 0 0 
Master mix Volume 18   0 
Template DNA 2   0 
Total Volume 20   0 
9. Re-cap PCR Master Mix tube, briefly vortex, spin down and place back in workstation. 
10. Take out a new 96 well plate from sealed bag. 
11. Use the multichannel pipette to dispense 18uL of MM from strip tubes into 96 well plate 
12. Inspect PCR plate to check that all appropriate wells have been filled and volumes appear consistent. 
Seal PCR plate. 
13. Remove sealed plate from PCR hood and set on bench next to hood. 
14. Take benchtop cooler back to main lab and put in -20°C freezer. 
15. Seal the waste container bag and remove from hood, dispose of bag into large container. 
16. Spray inside area of PCR hood with 10-20% bleach solution and wipe down thoroughly. 
17. Follow bleach with water and dry towel. 
18. Refill the tips, racks and other used items for the next assay and UV irradiate for 30 minutes 
19. Remove nitrile glove and replace with new gloves 
 
Amplification DNA Addition Station     
20. Inspect the DNA addition PCR hood to make sure all the consumables needed are present. 
21. Any items that are not present and have not been UV cleaned will need to be 20% bleach cleaned 
before being put into the PCR hood.  
22. Move the MM containing PCR plate into the hood.  
23. Remove the ligation product plate from the thermocycler and place it inside PCR hood. Remove 
and replace nitrile gloves.  
24. Remove seal from PCR plate, dispose and change gloves.  
25. Using the multichannel pipettor to dispense the ligation product from PCR plate. Remove 2uL of 
product from ligation plate and transfer it to MM PCR plate in the same location on plate.  
26. Add the ligated template DNA to their corresponding wells, then remove and replace gloves.  
27. Seal the plate using the foil adhesive sheets, making sure that all wells are firmly sealed. 
28. Remove plate from the PCR hood and set on the bench next to the hood. 
29. Seal the waste container bag and remove from hood, dispose of bag into large container. 
30. Spray inside area of PCR hood with 10-20% bleach solution and wipe down thoroughly. 
31. Follow bleach with water and dry towel 
32. Refill the tips, racks and other used items for the next assay and UV irradiate for 30 minutes. 
33. Remove gloves, followed by lab coat and leave in pre-PCR room. 
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34. Put on nitrile gloves before leaving pre-PCR lab. 
   
Amplification Post-PCR Lab 
1. Take sealed plate from pre-PCR lab into Post-PCR lab 
2. Place PCR plate into thermo cycler and run Amplification 
   
Amplification Conditions:  
1. 95°C  10 minutes 
2. 95°C  15 seconds 
3. 58°C  20 seconds 
4. 72°C  20 seconds 
5. Repeat Steps 2-4  45 cycles 
6. 72°C  7 minutes 
7. Hold at 4°C  
   
Hybridization Post-PCR Lab     
1. Enter the Post-PCR lab space and immediately put on lab coat, followed by nitrile gloves 
2. Open the MM PCR hood and place any tips, racks, Eppendorf tubes, TE buffer, and MES buffer 
needed for the day inside and turn on the UV light inside for  ~30 minutes, if not already done 
3. After the consumables have properly been irradiated by UV light, then proceed on to the next steps 
4. Retrieve Luminex beads from the refrigerator and place into MM PCR hood 
5. Vortex Luminex beads for 30 seconds inside MM PCR hood using centrifuge that has been UV 
irradiated.  
6. Aliquot 32 uL of each Luminex bead into one tube with 100uL MES buffer, centrifuge beads to a 
pellet, remove supernatant and suspend bead pellet in MES buffer.  
7. Aliquot the Luminex bead multiplex into 8-strip tubes for dispensing into PCR product plate.  
8. Add 10uL of 8-13plex Luminex beads to amplified PCR product 
9. Seal PCR plate and transfer plate to thermo cycler for hybridization 
 Hybridization Conditions     
 1. 95°C  3 minutes     
 2. 85°C   1 minute (Decrease by 10°C until reaching 55°C)  
 3. 50°C  30 minutes     
 4. 40°C  1 minute (Decrease by 5°C until reaching 25°C)  
 6. Hold at 25°C 1 hour     
     
10. Return to Post-PCR MM PCR hood and proceed with clean up 
11. Seal the waste container bag and remove from hood, dispose of bag in large container 
12. Refill the tips, racks and other used items for the next assay and UV irradiate for 30 minutes 
13. Remove gloves 
Addition of SAPE Post-PCR Lab     
1. Enter Post-PCR lab space and immediately put on lab coat, followed by nitrile gloves 
2. Open the MM PCR hood and place any tips, racks, Eppendorf tubes, TE buffer needed for the day 
inside and turn on the UV light inside for ~30 minutes, if not already done. 
3. Prepare SAPE by diluting 500ug/mL to 10ug/mL in TE buffer. (20uL SAPE in 980uL TE buffer) 
4. Remove PCR plate from the thermal cycler and place into MM PCR workstation 
5. Pour the diluted SAPE into origami reservoir.  
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6. Using multichannel to pull 50uL of SAPE from reservoir and use the tips to pierce the foil before 
dispensing into appropriate wells. Make sure the solution is at the bottom of the well.  
7. Incubate at room temperature for 30 minutes, inside of PCR hood under a box to protect from light. 
  
 Wash Steps Post-PCR Lab 
1. Place PCR plate with SAPE onto magnetic plate and leave there for 5 minutes inside of the PCR 
hood.  
2. Get a flat bottom 96 well plate and place it inside of the PCR hood.  
3. Inside of the PCR hood, dispense enough TE buffer into origami reservoir to add 100uL TE buffer 
into each well to be analyzed.  
4. After 5 minutes on the magnetic plate, remove the SAPE supernatant by removing the whole 
assembly from the hood, walk over to the sink.  
5. Place absorbent towels into the sink to catch the SAPE. Invert the entire assembly (plate and magnet) 
sharply over the towels once or twice to completely remove the SAPE. Try to keep all sample onto 
the towels. Dispose of towels into biological trash.  
6. Once done put the plate back into the hood and put the magnetic plate away in drawer.  
7. Use the multichannel pipettor to add 100uL of TE buffer to the first column on the plate to resuspend 
the pellet a few times. Use the same tips to remove the suspended pellets and place into the 96 well 
plate.  
8. Once all samples have been transferred to the 96 well plate, set samples next to post-PCR hood. and 
proceed with clean up 
9. Seal the waste container bag and remove from hood, dispose of bag in large container 
10. Spray inside area of PCR hood with 10-20% bleach solution and wipe down thoroughly 
11. Follow bleach with water and dry towel 
12. Refill the tips, racks and other used items for the next assay and UV irradiate for 30 minutes 
13. Remove gloves and replace with new nitrile gloves 
14. Proceed with running samples on Magpix     
15. After run, bleach (20%) soak all the counters inside and outside of this hood and wipe down the 
MagPix and counters near it with bleach solution.  
16. After soaking for about 30 minutes, wipe down with water. 
        
        
 
 
